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Abstract
THERAPEUTIC STRATEGIES AIMED
TO FACILITATE AXONAL REGENERATION AND FUNCTIONAL RECOVERY
FOLLOWING TRAUMATIC SPINAL CORD INJURY
By Woon Chow, B.S., B.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctorate of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2011
Major Director:  Raymond Colello, D.Phil.
Associate Professor, Anatomy and Neurobiology
Traumatic spinal cord injury (SCI) is a physically debilitating, emotionally 
devastating, financially costly, and life-changing condition that afflicts more than 
1,000,000 people in the United States alone.  Owing to the characteristic neuropathology 
and low regenerative capacity of the central nervous system, many victims of SCI are left 
permanently paralyzed.  Though the tissue damage caused by the initial insult almost 
certainly cannot be reversed, intensive research in recent years to elucidate the cellular 
and molecular events that follows has provided new grounds for optimism.  Accordingly, 
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in this dissertation, we present a number of potential treatment strategies aimed to address 
some of these pathological sequelae seen post-SCI so as to facilitate the regeneration of 
axons and the recovery of physiological functions.
After the initial traumatic insult, a prominent and lasting injury-induced 
proliferative response occur and results in the development of a gliotic scar that isolates 
the lesion from the surrounding viable tissue.  Although this process aids to prevent the 
spread of uncontrolled tissue damage, the scar nevertheless acts as a physical barrier to 
axonal regeneration.  Furthermore, cells within the scar are a major source of axon 
growth-inhibitory molecules such as chondroitin sulfate proteoglycans (CSPG) and thus 
the scar acts concomitantly as a biochemical barrier.  Concurrent to all this, inflammatory 
cells infiltrate the lesion and promote cell death through immunologic activation. 
Neuronal survival is also threatened from the lack of neurotrophic support caused by 
axonal severance.  Finally, the pathology culminates in the formation of a fluid-filled 
cyst, which represents a gap that further hinders axonal regrowth.
Since regeneration cannot physically occur in the presence of a cavity, we, by 
employing electrospinning techniques, generated a biocompatible matrix implant that can 
bridge and direct axonal elongation across the fluid-filled cyst.  Given the complex array 
and scope of pathological sequelae post-SCI, it is generally recognized that a 
multifaceted approach is required to successfully treat SCI.  In view of this, we presented 
novel approaches by which successful tried and true therapeutic strategies are combined 
xiii
to generate an enhanced matrix.  An enzyme as well as a growth factor was incorporated 
into our matrix implants in order to respectively neutralize CSPGs and provide 
neurotrophic support.  Using in vitro assays, we were able to demonstrate excellent 
protein bioactivity after incorporation.  In vivo experimentation of these enhanced 
matrices is now ongoing.  To address the injury-induced proliferative response, which 
represents an on-ramp off-ramp obstacle that prevents axonal regeneration onto our 
matrix implant, we showed how X-irradiation can be utilized to moderate this response 
by killing dividing cells so as to facilitate a more efficient penetration of regrowing axons 
into and beyond the gliotic scar.  Finally, we demonstrate how a novel pharmacologic 
agent FTY720 can be used to attenuate the inflammatory response by preventing 
lymphocytic egress from lymphoid tissues.
Collectively, these ideas and experimental results represent novel therapeutic 
strategies that can be combined in order to bring about meaningful functional recovery 
after SCI.
xiv
Chapter 1
Traumatic Spinal Cord Injury: the Epidemiological, 
Anatomical, and Pathological
Dissertation Synopsis
This dissertation investigates potential therapies that are directed at various 
therapeutic obstacles after traumatic spinal cord injury (SCI).  In Chapter 1, we discuss 
what is currently known about SCI, specifically the causes and classifications, pathology 
and associated therapeutic challenges.  In each of the following chapters, the discussion is 
then narrowed on a particular obstacle and a potential therapeutic strategy that addresses 
the obstacle.  Chapter 2 describes electrospinning and how that can be used to fabricate 
biocompatible implantable matrices to bridge the fluid-filled cyst.  The electrospinning 
discussion is expanded in Chapter 3 when we describe how these matrices can be 
supplemented with a neurotrophin and an axon growth-inhibitor neutralizing enzyme. 
Chapter 4 describes a preliminary study in which these enhanced matrices were 
implanted into a rat model of SCI.  Chapter 5 focuses on the injury-induced proliferative 
response and the potential of using X-irradiation to moderate this reaction.  These studies, 
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along with some concluding remarks, are summarized in Chapter 6.  In the appendix, we 
detail a potential pharmacologic intervention to suppress the inflammatory response.
Introduction
Traumatic injury to the spinal cord results in the severing of axons and cell death, 
leading ultimately to the disruption of communication pathways between the brain and 
distal targets and resulting in paralysis and loss of sensation.  A myriad of complex 
cellular and biochemical events follow the initial insult, which often further damages the 
cord parenchyma and reduces the permissiveness of the microenvironment to axonal 
regeneration.  Specifically, inflammatory cells infiltrate the lesion area and release toxic 
substrates, driving viable neurons and glia alike into apoptosis.  Glial cells at the border 
of the lesion epicenter react to the injury by hypertrophying and proliferating to form 
scar-like barriers and upregulating their expression of various axon growth-inhibitory 
compounds.  Concurrently, parenchymal destruction leads to the formation of a fluid-
filled cyst, resulting in a physical gap that further complicates the prospect of 
regeneration.  In short, the cellular and biochemical responses following SCI are 
numerous, complex, and possess certain elements of destruction.  Thus, potential 
treatments for SCI were generally unavailable until the last few decades.  And though 
little can be done to reverse the initial insult, through our increasing understanding of the 
pathology seen after SCI, new potential treatment strategies that target specific 
therapeutic obstacles can be devised and combined to bring about meaningful functional 
recovery.
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In this introductory chapter, we first present some general information about SCI 
including statistics, basic anatomy, and classifications before proceeding to discuss 
individually each of the major therapeutic obstacles that confront researchers and 
clinicians.  Later, in the remaining chapters, we shall describe our ideas and the 
investigations of these ideas for addressing each of these obstacles.
Epidemiological Statistics
The prevalence of SCI in the U.S. is often cited by the literature and various 
special interest groups to be from a conservative number of 200,000 (Berkowitz, 1998) to 
a higher estimation of 450,000 cases (National Spinal Cord Injury Association). 
Incidence is estimated to be approximately 11,000 cases each year (Berkowitz, 1998). 
However, a recent 2009 report from a project led by researchers at the University of New 
Mexico’s Center for Development and Disability suggests that there may be a gross 
underestimation of SCI prevalence in this country (Christopher & Dana Reeves 
Foundation).  The project, which included exhaustive surveys conducted on more than 
33,000 randomly sampled households, estimated that there may be an upward of 
1,275,000 people, or approximately 0.4%, of the U.S. population, currently living with 
SCI.  According to this newly generated report, more than 82% of the SCI cases were 
caused by trauma, with 28% of the cases resulting from occupational accidents, 24% 
from motor vehicle accidents, 16% from sport-related injuries, 9% from falls, 4% from 
violence-related injuries, and 1% from natural disaster-related injuries.  Paraplegia is 
documented in about 43% of SCI cases while quadriplegia in about 56%.  Of those 
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reported being paralyzed due to a SCI, 61% were males.  Currently, SCI costs the U.S. 
health care system approximately $40.5 billion annually, a four-fold increase from the 
estimated cost of 9.7 billion in 1998.  The considerable annual costs of living with SCI 
coupled with the overwhelming physical and emotional hardship suffered by both the 
patient and family make SCI an important public health concern that is worthy of finding 
a cure.
Spinal Cord Anatomy
Enclosed within and protected by the bony vertebral column in the spinal canal, 
the human spinal cord is a long, thin, soft, ovoid-shaped bundle of nervous tissue that 
extends inferiorly from the medulla oblongata at the level of the foramen magnum to 
typically the upper lumbar vertebral level.  Considered to be a part of the central nervous 
system (CNS) along with the brain, the spinal cord is similarly ensheathed by the three 
meninges, which include the outer dura mater, the arachnoid mater, and the innermost pia 
mater.  Cerebrospinal fluid is found in the subarachnoid space as in the brain as well as in 
the central canal, the adult remnant of the neural tube.  The peripherally located white 
matter of the spinal cord contains ascending and descending neural tracts of axons that 
act as signal transmission conduits between the brain and the rest of the body.  Damage to 
these tracts in a SCI causes a majority of the symptoms seen post-injury.  The centrally 
located gray matter contains neuronal cell bodies that are involved with motor control, 
reflexive loops, and central pattern generation.  Enlargements, which are portions of 
increased girth due to the greater amount of tissue needed to innervate the limbs, are 
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found at the cervical and lumbar levels.  In general across mammalian species, the more 
dorsal aspect of the cord contains tissue that are associated with afferent, or sensory, 
inputs and the more ventral aspect contains tissue that are associated with efferent, or 
motor, outputs.
The anatomy of the spinal cord and its surrounding structures plays a considerable 
role in explaining the favored level of injury in SCI.  SCI generally occur at the level of 
the cervical and lumbar cord, which is attributable to the presence of the enlargements at 
these locations.  Due to the compact physical space between the cord and the spinal canal 
at these vertebral levels, the spinal cord can easily be trapped and compressed if there is 
any orthopedic involvement when trauma occurs.  In contrast, mid-thoracic cord injuries 
are quite rare, since a small but significant space cushion exists between the cord and 
bone.
Spinal Cord Injury Pathological and Clinical Classification
Pathological Classification
Spinal cord trauma can be a result of any or the combination of the following: 
application of pressure such as stretching or squeezing, bruising, tearing, or crushing. 
The manner by which the spinal cord is injured has considerable influence on the 
prognosis as well as the therapeutic strategies involved.  Accordingly, a pathological 
classification, initially devised by Bunge et al. (1993), relates the manner by which the 
cord is injured to the gross appearance and histology of the cord seen at autopsies.  The 
four groups included in this classification are solid cord injuries, contusion/cavitation 
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injuries, laceration injuries, and massive compression injuries, with each of these types 
corresponding respectively to the manner of injury stated above.
Solid Cord Injuries
Solid cord injuries are SCI in which no gross defects are seen.  Grossly, the cord 
appears normal, with no softening, bruising, discoloration, or a compromise of the 
meninges.  However, histologically, sections show a loss of normal architecture, 
demonstrating the occurrence of damage (Figure 1.1B).  Solid cord injuries are rare and 
are only involved in about 10% of SCI cases.  The cause of solid cord injuries is still 
unclear, though inflammation is thought to play a major role in the development of these 
injuries.  It is suggested perhaps that a slight application of pressure on the cord, such as 
stretching or squeezing, which in itself is relatively harmless to cord tissue, is enough to 
trigger an inflammatory cascade.  The ensuing inflammation, as an insidious component 
of secondary injury, damages spinal cord tissue.  (Primary injury is the initial insult.)
Frequently, minor cases of SCI may not initially present with any clinical findings 
and only later does the patient begin to exhibit symptoms of a SCI.  This very fact 
supports the general notion that perhaps much of the tissue damage sustained after a 
primary SCI insult, especially in cases where cord anatomy was not drastically altered, is 
due to secondary injury.  Accordingly, the many notable potential therapeutic strategies 
to SCI and traumatic brain injury alike seen in the literature often target a component of 
secondary injury.
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Contusion/Cavitation Injuries
The second type, contusion/cavitation injuries, is the most common and is 
involved in more than half of all traumatic SCI cases.  Also known as percussive SCI, 
these injuries are usually caused by a dislocated vertebra or displaced discs and ligaments 
compressing and subsequently bruising the cord.  Grossly, there is no disruption of the 
pial surface despite the fact that often there are areas of hemorrhage in the central grey 
matter.  These areas eventually undergo liquefactive necrosis and the debris is 
subsequently cleared by inflammatory cells, ultimately resulting in the classical 
formation of a fluid-filled cyst (Figure 1.1C).  Concurrently, a prominent reactive 
astrogliotic reaction around the lesion site ultimately develops into a gliotic scar 
surrounding the cyst.
Laceration Injuries
The third type, laceration injuries, account for about 20% of SCI cases.  Often, 
these injuries are a result of broken fragments of vertebra cutting the cord.  Gun-shot and 
stab wounds are also responsible.  In contrast to contusion/cavitation injuries, rupturing in 
the pial membrane is apparent (Figure 1.1D).  As a consequence, extra-medullary 
fibroblasts migrate into the lesion site, deposit a substantial quantity of collagen, and 
ultimately form a mesenchymal scar.  The prognosis of laceration injuries is often poor 
since the dense scarring characteristically blocks any attempts of axonal regrowth or 
rewiring.  Minor functional improvements can often be seen in SCI patients post-trauma 
as the injury stabilizes, but this rarely occurs in laceration SCI.
7
Massive Compression Injuries
Finally, in massive compression injuries, the cord is essentially crushed, usually 
from extensive orthopedic trauma.  The pathological evolution of these lesions is similar 
to that of laceration injuries due to the pial disruption.  Accordingly, considerable fibrosis 
and dural adhesion typically results (Figure 1.1E).  Less than a 20% of traumatic SCI 
cases are classified as massive compression injuries.
Most SCI cases can be classed as one of these four types.  However, some 
injuries, especially multi-level ones, may involve more than one of these pathologies. 
Outwardly, this pathological categorization scheme seems somewhat overly simplified, 
but nevertheless helpful when prognosticating the progression of a SCI.  
Clinical Classification
In contrast to the pathological classification, a clinical classification of SCI is 
based on the functional implications post-injury.  In general, SCI can be classified as 
complete, incomplete, or discomplete.  Complete injuries usually involve trauma so 
severe that there is total paralysis and sensation loss below the level of the lesion.  This 
clinical type frequently implies a total cord transection, which is an exceptionally 
uncommon event.  In contrast, incomplete injuries signify that some physiological 
function is preserved below the injury level.  The implication here is that the cord has not 
been completely severed.  In many cases of incomplete injury, the cord is generally 
anatomically intact but the injury has caused disruption in some but not all the neural 
tracts.  Finally, discomplete injuries appear to be clinically complete but 
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neurophysiologically incomplete.  Patients with this type of injury are completely 
paralyzed below the lesion, but they exhibit some brain influence on spinal cord function. 
This presentation of SCI has not been fully explained and the cause is still unclear. 
Generally, once a SCI patient is stable after admission, he or she often undergoes 
extensive testing to determine the completeness as well as the physiological level of 
injury.  This evaluation includes assessing the three major afferent and efferent spinal 
cord pathways, specifically the dorsal column tracts with pinpricks and the spinothalamic 
tracts with light touches at all dermatomes plus the corticospinal tracts with muscle 
strength tests on all major muscle groups.
These classifications convey the varieties and range of clinical and pathological 
consequences after SCI.  Accordingly, SCI treatment strategies must be tailored to the 
specific injury type.
The Obstacles to Successfully Treating Spinal Cord Injury
In this project, we were most interested in furthering our understanding of and 
testing improved potential therapies for contusion/cavitation typed SCI since as 
aforementioned, they are the most common cases clinically.  In the following sections, 
the therapeutic obstacles to successfully treating this percussive type of SCI are 
discussed.  These obstacles, as well as our therapeutic ideas for addressing them, are 
revisited in the remaining chapters individually.
In short, percussive injury to the cord in both humans and animal models results 
in a pathological cascade of cellular and molecular events that culminate in the 
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characteristic formation of a fluid-filled cyst enclosed by a cellular wall made by the 
proliferation of glial cells and subsequent scarring (Balentine, 1978; Wozniewicz et al., 
1983; Kakulas, 1984; Bresnahan et al., 1991; Bunge et al., 1993; Ito et al., 1997; 
Norenburg et al., 2004).  The cyst forms a physical gap within the cord parenchyma, 
preventing axons from crossing the lesion to reach downstream targets.  The gliotic scar, 
formed by the hypertrophy and hyperplasia of various cells in and around the lesion, 
presents a physical as well as biochemical barrier due to the increased cellular expression 
of compounds that inhibit growth cone migration (Lemons et al., 1999; Morgenstern et 
al., 2002).  In addition to these pathological hallmarks, inflammation, mentioned 
previously as a component of secondary injury, plays an insidious role in the promotion 
of cellular apoptosis, exacerbating the damage initially sustained by the primary insult 
(Anderson et al., 1985; Blight, 1992).  Furthermore, the loss of trophic support 
exacerbates neuronal cell death.  These SCI pathological features of scar development, 
inflammation, cavity formation, molecular inhibitors, and loss of trophic support are now 
discussed in greater detail.
Cyst Formation
Though cystic formations generally occur late in the pathologic evolution of the 
SCI lesion, we initiate our discussion with this topic since they represent the single most 
prominent obstacle to axonal regeneration.  Customarily found in contusion/cavitation 
injuries, fluid-filled cysts typically form at injury epicenters weeks to months following 
SCI (Balentine, 1978; Norenburg et al., 2004).  Cysts may have a singular, multiple, or 
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multiloculated presentation and a wall of gliotic scarring, deposited during the lesion-
isolation process, surrounds the cysts.  The cysts are essentially the end products of debris 
clean-up at the lesion site and they represent the final healed state of a CNS injury. 
Similar to cysts in that they are fluid filled, syrinxes, differ in that they possess a thicker 
and denser gliotic wall due to increased pressure in the cavity.  Syrinxes may exacerbate 
existing neurological deficits since adjacent cord parenchyma may be compress as the 
cavity increase in size.  Cavity formations are yet another obstacle in successfully treating 
SCIs.  Due to the lack of a solid substrate, this pathological endpoint represents a 
physical gap that prevents regenerating axons from crossing to reach their downstream 
targets.
To this end, in Chapter 2, we show how electrospinning was utilized to fabricate a 
bridging matrix.  Recognizing that an ideal bridging scaffold would be biocompatible, 
durable, porous, and directional such that it can spatially guide regrowing axons, we 
generated via electrospinning a matrix that possess all of these properties and 
demonstrated their excellent neurite-guiding ability in vitro.  Furthermore, in Chapter 3, 
in preparation for the assessment of these matrices in vivo, we show how we refined the 
electrospinning process by adopting an air-gap spinning system so as to generate 
implantable 3-dimensional cylindrical structures possessing the same qualities that are 
capable of filling the gap left within the damaged cord.  A preliminary test of these 
matrices in an animal model of SCI is presented in Chapter 4.
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Chondroitin Sulfate Proteoglycans
After SCI, glial cells within the scar and in the surrounding lesion zone proliferate 
and hypertrophy to form the gliotic scar.  In addition, these cells upregulate their 
expression of CSPGs (Lemons et al., 1999).  CSPGs are well-known inhibitors of axonal 
regeneration (McKeon et al., 1995; Canning et al., 1996; Gopalakrishnan et al., 2008; 
Yang and Schnaar, 2008).
Chondroitin sulfate is simply a sulfated glycosaminoglycan (GAG), which is a 
long unbranched polysaccharide consisting of a variable number of repeating 
disaccharide units.  One or more of these chains are often found attached to a core protein 
via a serine residue as part of a proteoglycan.  Depending on the core protein to which the 
GAG chain is attached, the entire molecule is called by a distinctive name.  Examples of 
CSPG molecules include aggecan, brevican, neurocan, phosphacan, versican, and NG2. 
The pattern of sulfation can be rather complex as each disaccharide possesses four 
possible positions for group attachment and the diseaccharide may be unsulfated or 
sulfated in 1, 2, or 3 positions.  For this reason, there can be a very large number of 
sulfation motifs which defines the individual binding site.
CSPGs are expressed almost ubiquitously and are found in the ECM of most 
tissues.  In addition to their structural role in the ECM, these molecules are important 
regulators in various biological processes involving cellular recognition, migration, and 
signaling (Brittis et al., 1992; Sheng et al., 2005).  In certain tissues, they provide very 
specific functions.  For example, CSPGs are a major component of cartilage and by virtue 
of their numerous tightly packed and highly negatively charged sulfate groups, generate 
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the electrostatic repulsion that provides much of the compression resistance.  In the 
nervous system, they contribute to the regulation of various CNS developmental 
processes, acting as a stop signal to neuronal and axonal growth cone migration (Powell 
et al., 1997; Cortes et al., 2009).
Upon injury to the CNS, there is a general massive upregulation of CSPGs at the 
lesion site and surrounding areas (Lemons et al., 1999).  Although this expression usually 
peaks during the first week post-injury, levels of CSPG usually stay high as the gliotic 
scar matures (Tang et al., 2003).  The production of a certain CSPG is attributable 
generally to a particular cell type.  Brevican and phosphacan are mainly products of 
astrocytes whereas versican and NG2 are almost exclusively expressed by 
oligodendrocyte progenitor cells (OPC) (McKeon et al., 1999; Asher et al., 2002; 
Bouslama-Oueghlani et al., 2005).  Neurocan is produced by both astrocytes and OPCs 
(Asher et al., 2000).
The exact mechanism by which CSPGs inhibit the regeneration of axon is still 
unclear.  Substantial evidence suggests that the sulfated GAG chains are the elements 
responsible.  Nevertheless, it is well-recognized that successful SCI therapies include an 
element that targets these nefarious molecules so as to neutralize their axon growth-
inhibitory property.  In vitro experimentation by various research groups with the 
bacterial enzyme chondroitinase ABC (ChABC), which cleaves the GAG chains, have 
shown a drastic reduction of the inhibitory activity of CSPGs (Iaci et al., 2007; Massey et 
al., 2008).  Furthermore, recent in vivo studies using ChABC demonstrated enhanced 
axonal sprouting and neuroplasticity as well as improved functional recovery (Bradbury 
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et al., 2002; Caggiano et al., 2005; Huang et al., 2006; Tester and Howland, 2007).  In 
view of these successes by others, in Chpater 3, we show how we integrate ChABC into 
our implantable electrospun matrices as well as present data from in vitro assays that 
demonstrate the extent to which the enzyme remained bioactive.
Neurotrophins
Neurotrophic factors, or neurotrophins, are small, secreted peptides that act on 
cells in the nervous system via specific receptors that activate intracellular signaling 
cascades to promote cell survival, growth, and differentiation (Markus et al., 2003).  In 
general, neurons projecting axons via specific tracts within the spinal cord respond to one 
particular neurotrophin or a collection of factors.
The nerve growth factor (NGF) family of neurotrophins includes the four related 
peptides that share structural and sequence homology: NGF, brain-derived neurotrophic 
factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4).  These factors can 
bind to two entirely distinct classes of receptors.  The first known targets, Trk 
(tropomyosin receptor kinase) receptors are a family of tyrosine protein kinase receptors 
that mediates high affinity binding.  Each of the Trk receptor members bind only with 
specific neurotrophins.  TrkA receptors, which are expressed by sympathetic, trigeminal, 
and dorsal root ganglion neurons as well as by cholinergic neurons of the striatum and 
basal forebrain, specifically recognize NGF (Barbacid, 2004).  TrkB receptors are 
activated primarily though their binding with BDNF and NT-4.  The principal targets of 
NT-3 are TrkC receptors, which have been shown to be expressed on developing 
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corticospinal neurons (Chen et al., 1996, Namiki et al., 2000; Iarikov et al., 2007).  In 
some cellular contexts, NT-3 is also able to bind TrkA and TrkB, though with less 
efficiency.  Activation of the Trk class of receptors results in the prototypical function of 
neurotrophins, namely the promotion of cell survival and growth.  The second known 
target (though first discovered) of neurotrophins is the p75 neurotrophin receptor 
(p75NTR), a member of the tumor necrosis receptor superfamily.  In contrast to the Trk 
family, all four mentioned neurotrophins are able to bind to p75NTR, although with 
much less but similar affinity.  The specific role of p75NTR is not entirely clear.  Due to 
their low affinity for the neurotrophins, some have suggested that p75NTR may act to 
take up excess concentrations and affecting neurons in a manner beyond survival and 
growth in such occasions.  The p75NTR is known to be highly expressed in certain 
developing neurons as well as in axotomized adult neurons, which suggests a 
physiological role in mediating the higher neurotrophin expression by the local glial cell 
population seen after trauma.  It has been demonstrated that p75NTR increases both the 
binding affinity and specificity for Trk receptor.  This is especially evident with NGF in 
that both p75NTR and TrkA are required for the efficient generation of high affinity 
binding sites (Esposito et al., 2001).  However, other studies have point to the role of 
p75NTR as a pro-apoptotic mediator.  Cells expressing P75NTR in the absence of Trk 
receptors may be driven to programmed cell death in the presence of a neurotrophin 
rather than surviving (Teng et al., 2005).  Another interesting observation related to SCI 
is the relationship between the p75NTR and Nogo-66 receptor.  The Nogo-66 receptor, 
with its downstream Rho kinase pathway, is responsible for mediating the inhibitory 
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effects on axonal growth of three notorious myelin-associated glycoproteins, specifically 
Nogo-A, myelin-associated glycoprotein and oligodendrocyte-myelin glycoprotein (Liu 
et al., 2002; Xie and Zheng, 2008).  The p75NTR receptor act as a co-receptor to the 
Nogo receptor complex and when p75NTR was knocked out in mice, outgrowth 
inhibition of axons was no longer observed (Wang et al., 2002; Wong et al., 2002).  In 
short, though the meaning of the association between P75NTR and Trk, with some 
seemingly synergistic and others antagonistic effects, is still quite controversial, it is 
apparent that there are independent and dependent roles and actions of these two types of 
receptors.
After ligand binding, the high affinity Trk receptors undergo dimerization and 
autophosphorylates tyrosine residues in their cytoplasmic domains.  The neurotrophins 
and its activated Trk receptors are subsequently internalized through clathrin-coated pits 
and conveyed retrogradely up the axon toward the neuronal soma.  This endocytosis and 
subsequent vesticular transport serves to bring the activated signal close to certain 
organelles, such as the nucleus, where the signal can be acted upon to bring about 
specific cellular responses by way of gene transcription.  Signaling in the neuronal cell 
body controls the more global cellular functions of survival, proliferation, and 
differientation (Jacobson et al., 1997).  In contrast, local signaling is also known to occur 
and has been shown to regulate growth cone motility (Thoenen and Barde, 1980).  In one 
study, Gallo et al. was able to demonstrate that the TrkA receptor mediated growth cone 
turning toward a localized source of NGF (1997).  The molecular mechanisms by which 
neurotrophins regulate growth cone motility are not well understood.  However, recently 
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acquired experimental evidence suggests that these Trk-dependent actions may converge 
downstream with the abovementioned Rho kinase pathway and that a local accumulation 
of actin filaments may result from an increase in intracellular calcium concentration 
(Gehler et al., 2004).
In general, neurons in the CNS obtain their trophic support from the target tissue 
to which their axons project and this secretion of neurotrophins by the target tissue 
prevents the associated neuron from initiating apoptosis.  Thus, a low maintenance level 
of neurotrophins is required to ensure neuronal survival.  Upon axotomy after SCI, the 
disconnected neurons no longer receive a survival signal and may be driven into 
programmed cell death.  However, studies have shown that exogenous introduction of 
neurotrophins after CNS injury rescues these axotomized neurons, ensuring cell survival 
and in many cases cause enhanced axonal regrowth (Namiki et al., 2000; Mitsui et al., 
2005; Blesch and Tuszynski, 2007).  Accordingly, also in Chapter 3, we describe the 
incorporation of NGF into our implantable electrospun matrices by way of alginate 
microspheres and present data from in vitro assays that demonstrate the extent to which 
the growth factor remained bioactive when incorporated.
Reactive Astrogliosis and Gliotic Scar Formation
In human percussive SCI, the reactive astrogliotic, or gemistocytic, response is 
characterized by cellular hypertrophy and injury-induced proliferation, which ultimately 
results in a gliotic scar that is classically seen around the boundary of the lesion epicenter 
(Figure 1.2).  This outcome brings about a number of neuroprotective benefits.  As a new 
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glia limitans forms, reactive gliotic processes interdigitate and become linked by tight 
junctions.  This functions to isolate the SCI lesion containing necrotic tissue debris from 
viable tissue in the periphery, resulting in the reestablishment of the integrity of the CNS 
microenvironment within and aiding to prevent a further spread of cellular destruction 
(Norenburg et al., 2004).  Astrocytes within the developing gliotic scar are known to play 
a homeostatic role in restoring extracellular ionic balance and uptaking of the excess 
excitatory neurotransmitters and other toxic metabolites that may have accumulated in 
the lesion and the surrounding cord tissue (Davies et al., 2006; White and Jakeman, 
2008).  Furthermore, as the gliotic scar forms, reactive astrocytes often extensively 
remodel the extracellular matrix (ECM) and lay down abundant deposits of basal 
membrane.  Analogous to wound contracture after skin injuries, this basal membrane can 
contract to bring together opposite margins of the lesion, shrinking the lesion as debris is 
cleared out.  In addition, the gliotic scar provides a cellular scaffold for inwardly 
migrating epithelial cells to revascularize the lesion site.
In contrast to the above benefits, the scar has been implicated in blocking axonal 
regeneration physically as well as biochemically via the expression of chondroitin sulfate 
proteoglycans (CSPG) and other inhibitory factors.  First causally suggested by Ramón y 
Cajal (1928), subsequent experimental results readily confirms that though regenerating 
CNS axons sprout growth cones, axonal regrowth and growth cone migration invariably 
stop at the gliotic scar border (Reier et al., 1986).  The cause of the physical barrier is still 
unclear.  Though the gliotic scar is sealed sufficiently to prevent the spread of damage 
peripherally from the lesion epicenter, many studies have shown that astrocytic processes 
18
and their associated tight junctions do not create a physical impediment (Norenburg et al., 
2004).  However, there is a possibility that the basal membrane is capable of obstructing 
axonal regrowth due to its contractile properties, resulting in its dense architecture. 
Consequently, success in inducing regenerating axons to regrow past the scar to seek 
distal targets requires a physical alteration of the scar to some extent.
In view of the inability of regenerating axons to penetrate the scar to reach our 
implantable electrospun matrix scaffold and off on the opposite side, in Chapter 5, we 
present a potential non-invasive therapy in which single-dose X-irradiation is used to 
moderate the injury-induced proliferative response so as to increase the spatial separation 
between reactive cells, which may create small gaps to facilitate regeneration at the on-
ramp and off-ramp sites adjacent to the matrix.  The attenuation of cellular proliferation 
needs not be extreme since gliotic scarring nevertheless confers important 
neuroprotective benefits.
Edema and Inflammation
Edema is often the first gross sign following SCI that can be detected, usually 
radiographically.  This edema is probably due to the vascular changes, namely 
vasodilation and hyperemia, which occur early on in the injury response (Sharma et al., 
1993).  Specifically, a breakdown of the blood-spinal cord barrier, loss of cerebral 
autoregulation, and the consequent increased permeability of capillaries results in an 
exudation of plasma fluid into the extracellular space.  This vasogenic edema can cause 
an ischemia that may possibly be due to the increased hydrostatic pressure in the region. 
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In contrast to the brain, the spinal cord has a thicker and perhaps more rigid pial-glial 
zone, which can exacerbate this ischemic mechanism.  This ischemia can in turn cause a 
buildup of undesirable metabolites and excitatory neurotransmitters, causing more 
neurons in the vicinity to die (Stiefel et al., 2005).  Research completed at this institution 
has shown that perhaps more significant than vasogenic edema is the cytotoxic edema 
that may be caused by these events (Marmarou et al., 2006).  This mostly occurs in 
astrocytes, especially those with astrocytic end-feet adjacent to capillaries (Bullock et al., 
1991).
The basis for the increased permeability of the blood-spinal cord barrier is 
attributed generally to a host of secreted factors.  It is well-established that expressions of 
pro-inflammatory cytokines such as Interleukin (IL)-1, IL-3, and IL-6 as well as their 
associated receptors are strongly upregulated post-injury.  In addition, various 
complement components and tumor necrosis factor (TNF) were also observed to be 
increased in their expression.  These and a number of other factors, such as various 
matrix metalloproteinases, may be responsible for the enhancement of vascular 
permeability and the subsequent infiltration of immune cells.  Furthermore, the sustained 
elevations of particularly TNFα and IL-1β may cause neuronal and oligodendroglial cell 
death (Lee et al., 2000; Hermann et al., 2001; Cai et al., 2003).  Accordingly, blocking 
TNFα and IL-1β have shown to be neuroprotective in various models of CNS trauma 
(Nesic et al., 2001; Genovese et al., 2006).  Though it is recognized that cytokines play 
an important and seemingly destructive role in mediating the inflammatory reaction 
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following SCI, the full extent of involvement by these various pro-inflammatory factors 
on the secondary degenerative processes remains unclear.
As mentioned, the cytokine mediated vascular changes attract inflammatory cells 
into the lesion site (Trivedi et al., 2006).  As shown in animal studies, compared to post-
traumatic inflammation in brain injuries, SCI tends to elicit a more prominent cellular 
immune response (Schnell et al., 1999a).  Following identical laceration injuries 
delivered to mouse brain and spinal cord, higher numbers of neutrophils and activated 
macrophages were shown to be recruited to the SCI lesion site and their extent of 
infiltration was more profound.  In a subsequent study by the same group, similar results 
were obtained when non-traumatic injections of pro-inflammatory cytokines into the two 
different tissues—neutrophil and macrophage recruitment was always greater in the 
spinal cord (Schnell et al., 1999b).  Anatomical and molecular variabilities between the 
brain and spinal cord may account for these regional differences in inflammatory 
reactions (Tveten, 1976a, b).  Nevertheless, these results demonstrate that knowledge and 
data gleaned from studying CNS inflammation in the brain cannot be applied to SCI 
without further examination.
After injury to the cord parenchyma, blood monocytes, granulocytes, and 
lymphocytes readily migrate across the permeable blood-spinal cord barrier.  It has been 
demonstrated numerous times that immune cell infiltration into the SCI lesion site largely 
contributes to the secondary injury process and may considerably expands lesion volume 
(Dusart and Schwab, 1994; Blight et al., 1995; Glaser et al., 2004).  The earliest arrival of 
neutrophils usually occurs within 12 h with ED1 immunoreactive macrophages appearing 
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soon after (Carlson et al., 1998; Norenburg et al., 2004).  These cells phagocytose cellular 
and myelin debris and begin the intensive clean-up process that may continue for the next 
3 to 5 d.  By day 3, numerous fat-laden macrophages occupy the lesion site.  Though the 
process of debris removal in itself is beneficial, many researchers have suggested that a 
number of elements may perhaps be neurotoxic.  Neutrophils release a potent cocktail of 
reactive oxygen species and enzymes intended for a bacterial invasion.  It is almost 
certain that neutrophils confer no meaningful neuroprotection in the CNS post-injury 
given their foremost function as bactericidal cells.
Lymphocytes, in particular the T cell, have been implicated in promoting cellular 
apoptosis following the release of neural self-antigens and the resulting activation of 
immunological cascades after CNS injury (Popovich et al., 1996; Gonzalez et al., 2003; 
Ankeny et al., 2006).  In experimental trials, injection of activated T cells from SCI rats 
alone has shown to cause CNS injury in naïve animals (Popovich et al., 1996). 
Consequently, one element of a successful SCI therapy must include a means to modulate 
the inflammatory response so as to reduce cell death and preserve the enduring viable 
tissue parenchyma surrounding the lesion site.
Accordingly, in the appendix, we present a potential pharmacologic therapy that 
aims to induce lymphopenia following SCI.  By preventing lymphocytic egress from 
lymph nodes, we show the extent to which fingolimod, commonly known as FTY720, 
preserves cord white matter, improves bladder function, and enhances functional 
recovery.
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Summary
Figure 1.3 illustrates and summarizes the major therapeutic challenges posed by 
SCI that we have just now discussed.  Given the multitude and the variety of obstacles, 
SCI is a costly, debilitating, and life-changing medical condition that will require a 
combination of approaches to successfully treat.  In the following chapters, we will 
present our ideas and the investigations of these ideas for addressing each of these key 
challenges.
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Figure 1.1.  (A) Cross sectional histology of a normal human spinal cord at the cervical 
level.  (B) Cords in solid cord injuries display a loss of the normal tissue architecture. 
(C) Cystic formation in cord parenchyma in contusion/cavitation injuries.  (D) Pia is 
penetrated in laceration injuries.  (E) Massive compression injuries generally results in 
the pulpification of cord tissue and extensive hemorrhage.  Scale Bars (A to E) = 2 mm. 
Adapted from Norenberg et al. (2004).
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Figure 1.2.  (A) Longitudinal sections of a rat spinal cord, which received a contusion 
injury 14 d earlier, immunolabeled for GFAP (red).  Gliotic scarring is readily seen by 
the high intensity of labeling around the edge of the developing cyst located at the lesion 
epicenter.  (B) The same section immunolabeled for bromodeoxyuridine (green), a 
proliferation marker.  Scale Bars (A and B) = 1 mm.
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Figure 1.3.  A cartoon illustrating the various therapeutic challenges posed by 
contusion/cavitation SCI.  Adapted from Fitch and Silver (2008).
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Chapter 2
Evaluating Neuronal and Glial Growth on Electrospun 
Polarized Matrices
Introduction
Percussive injury to the spinal cord, in both human insults and animal models, 
results in the liquefactive necrosis of the tissue in and around the lesion site.  Commonly, 
a fluid-filled cyst is the final consequence of this process.  Because of the lack of a solid 
substrate, this late-stage pathological endpoint presents a physical gap which impedes 
axonal regeneration and functional recovery after spinal cord injury (SCI).  Though other 
therapeutic obstacles exist post-SCI, the cystic formation represents a single most 
formidable challenge to axonal regrowth.
To guide regenerating axons across this cavity, several research groups have 
investigated the use of bridging materials that include substrates derived from either stem 
cells (McDonald et al., 1999; Akiyama et al., 2002), support cells (Xu et al., 1995; Li et 
al., 1997), autologous grafts (von Wild and Brunelli, 2003; Houle et al., 2006), 
embryonic grafts (Reier et al., 1986), natural substances (Marchand et al., 1993), or 
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synthetic substances (Tsai et al., 2004; Wen and Tresco, 2006).  Many of these 
approaches have shown promise in attracting regenerating axons onto the prosthetic 
bridge.  However, documented cases of axons traversing these conduits to reach the intact 
tissue on the opposite margin of the lesion area are rare.  Consequently, successes in 
inducing axonal regeneration have not translated into appreciable recovery of function. 
Nevertheless, despite the failure of significant axonal regrowth on existing bridges, 
advances in generating conduits for growth across lesioned areas must be made to 
successfully restore function after SCI.
In a simplified view, an ideal bridging neural conduit would be made from a 
biocompatible material that contains either channels or fibers that spatially guide 
regenerating axons.  Since damage to the spinal cord induces necrosis that frequently 
affects multiple fiber tract systems, this bridge should fill the extent of the cyst area. 
Additionally, it should have a level of porosity that allows the inward migration and 
incorporation of supportive cells as well as the traversing axons.  Finally, the ideal bridge 
should have the capacity to deliver signaling factors in a controlled manner to aid in the 
attraction, directional growth, and viability of traversing regenerating axons.  One 
technique that has the capacity to generate such an ideal bridging prosthesis is 
electrospinning.  Similar in concept to electrospraying, electrospinning uses a high-
voltage electric field to generate extremely fine fibers that are deposited on a grounded 
collector to form a nonwoven mat (Bowlin et al., 2002).  Chemically, these mats can be 
electrospun from either extracellular matrix (ECM) proteins or synthetic polymers, both 
of which can be spun alone or in combination with other growth-promoting factors. 
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Physical properties of these matrices, such as fiber diameter, porosity and alignment can 
also be controlled (Fridrikh et al., 2003).  In the field of tissue engineering, the 
application of this technique has resulted in the generation of several biocompatible 
substrates such as growth-promoting dermal implants, cardiac patches, and synthetic 
vessels (Stitzel et al., 2001; Sun et al., 2005).  For example, studies show that interstitial 
fibroblasts and endothelial cells migrate readily into an implanted electrospun collagen 
matrix from surrounding tissue (Telemeco et al., 2005).  Once there, these cells 
proliferate and actively remodel this biological substrate, resulting in accelerated wound 
repair with less contracture.  More recently, electrospinning has been used to generate 
growth matrices for cortical stem cells (Yang et al., 2005).  Collectively, these studies 
indicate the potential utility of electrospining to create biocompatible substrates for use in 
injury repair.
In the study presented in this chapter, we examined the potential use of 
electrospinning to engineer a polarized matrix for axonal guidance.  This matrix, which 
was spun from the resorbable suture material, polydioxanone (PDS), was tested for 
biocompatility with cells of neuronal and glial origin, and the growth dynamics of these 
cells on the matrix were assessed in cell culture studies.  These experiments demonstrate 
that both the directionality and exuberance of axonal growth are controlled significantly 
by the physical and chemical properties of the underlying electrospun substrate. 
Controlling these two parameters of axonal growth are prerequisites to establishing a 
successful strategy for bridging lesioned areas in SCI.
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Materials and Methods
Electrospinning
Electrospun matrices were fabricated from the PDS II violet monofilament 
surgical suture (Ethicon) as described previously (Boland et al., 2005).  Briefly, for each 
matrix, 150 mg of 10% weight/volume of cut PDS filament was dissolved overnight in 
the solvent 1,1,1,3,3,3-hexafluoro-2-propanol. The solution was then transferred to a 5-ml 
syringe tipped with an 18-gauge blunt-end needle (Kontes) and the syringe mounted onto 
a syringe pump set at a delivery rate of approximately 30 ml/hr.  The needle was 
connected via a wire outfitted with an alligator clip to the positive output lead of a high 
voltage direct current (DC) power supply (Spellman CZE1000R) set to 22 kV.  The 
grounded rectangular mandrel, with a cross-section of 10 × 3 mm, was placed 20 cm 
from the needle (Figure 2.1).  An electric field was generated across the nozzle and the 
grounded mandrel, inducing a jet of solution to be drawn out from the syringe and 
resulted in the deposition of a solid fiber core onto the rotating mandrel (Taylor, 1964). 
By varying the rotation rate of the mandrel, as determined by a calibrated digital 
stroboscope (Shimpo Instruments DT-311A), aligned and random fibers with diameters 
of 2 to 3 mm could be generated (Figure 2.2).  Specifically, a faster rotation rate of 5000 
rpm was used to spin matrices of aligned fibers (aligned matrices) whereas a slower 
rotation rate of approximately 10 rpm or less generated randomly oriented fibers (random 
matrices).  Additionally, an even distribution of the fibers on the mandrel was achieved 
by allowing the mandrel assembly to translate (0.5 Hz).
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Scanning electron microscopy
To prepare the matrices for scanning electron microscopy (SEM), 1-mm squares 
of both aligned and random matrices were cut from the electrospun mat and sputter-
coated in gold.  Photomicrographs (750 ×) were taken of random areas in each matrix, 
digitized with a flatbed scanner, and analyzed for fiber alignment using 2-dimensional 
fast Fourier transform (2D FFT).
2-Dimensional Fast Fourier Transform Alignment Analysis
As previously described by this laboratory (Alexander et al., 2006), utilizing the 
FFT function of the ImageJ image processing software, an image containing a graphical 
representation of the frequency content was generated from a digitized, square, grayscale 
image of the elements to be analyzed.  Pixel intensities and the distribution of the 
intensities (frequency content) of this output image correlate to the directional content of 
the original image.  Pixel intensities were summed along a radius from the center to the 
edge of the image to quantify the relative contribution of objects oriented in that 
direction.  This summing was repeated at 1° increments around the image and the 360 
summations were plotted.  In this manner, a 2D FFT of an image containing randomly 
oriented elements results in relatively constant pixel intensities independent of direction. 
Theoretically, a radial summation of this type of data set should be represented as a flat 
line; however, because of edge effects associated with square images, an undulating plot 
with four small, symmetrical peaks results.  In contrast, a 2D FFT of an image that has 
elements that are aligned preferentially would result in higher pixel intensities along the 
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aligned direction.  Accordingly, when the radial summations are plotted, two peaks, 
representing the two angles (180° apart) associated with the aligned elements in an image 
are generally seen (Ayres et al., 2006, 2008).
Dorsal Root Ganglia Isolation and Culture
In this study, the potential of aligned matrices to influence the growth dynamics 
of extending dorsal root ganglion (DRG) neurites was tested.  A set of random matrices 
was used as controls.  In accordance with the Virginia Commonwealth University 
Institutional Animal Care and Use Committee, DRGs were dissected from embryonic day 
16 (E16) Sprague Dawley rats as described previously (Sharma and Bigbee, 1998). 
Briefly, following removal from the uterus, the developing spinal cord from each embryo 
was exposed anteriorly.  The entire cord was dissected from its rostral end and placed in 
Leibovitz L-15 media with 10% fetal bovine serum (FBS).  The attached DRGs were 
then plucked off with fine tip forceps.
Circles of aligned and random matrices of 8-mm in diameter were sterilized in 
100% ethanol, rinsed in Hank’s balanced salt solution, and secured on the bottom of a 35-
mm diameter Petri dish using hypodermic needles.  Using a dissection microscope, 
several DRGs were micropipetted onto each matrix and pinned in place with 0.15-mm 
diameter minuten pins (Austerlitz). Cultures were incubated at 37°C with a 95% air/5% 
CO2 gas mix in Eagle’s minimum essential medium with glutamine supplemented with 
10% glucose, 5% FBS and 0.01% 2.5 S nerve growth factor.  The medium was changed 
every 2 d, alternating between the above medium and medium containing the antimitotic 
35
agent, 5-fluorodeoxyuridine (10-5 M), which limits the proliferation of Schwann cells in 
DRG cultures (Wood, 1976).  Following a 10-d incubation, the cultures were fixed in 4% 
paraformaldehyde in 0.1 M phosphate-buffered saline (PBS).  Following fixation, DRG 
cultures were immunostained for the β-tubulin neuronal marker TuJ1 (Covance). Cultures 
were first blocked for 30 min in a solution consisting of PBS with 10% FBS and 0.3% 
Triton X-100, incubated for 2 h in a 1:500 dilution of TuJ1 mouse primary antibody in 
PBS and visualized with a 1:200 dilution of Alexa Fluor 488 goat anti-mouse secondary 
antibodies (Invitrogen) in PBS.  Subsequently, 6 × digital, wide-field, fluorescence 
images of the DRG and its neuritic outgrowth were obtained using an Olympus BX51 
microscope.  For this study, DRGs were pinned on at least six matrices (three aligned and 
three random) and the experiment was repeated at least three times.
Astrocytic isolation and culture
In this study, the potential of aligned matrices to influence growth dynamics of 
astrocytes was tested.  A set of random matrices was used as control.  In accordance with 
the Virginia Commonwealth University Institutional Animal Care and Use Committee, 
rat primary astrocytes were isolated using methods described previously (McCarthy and 
de Vellis, 1980).  Isolated postnatal day 3 (P3) rat cortices were minced and dissociated 
mechanically and enzymatically.  Cells were seeded into T-75 poly-L-lysine-coated 
tissue culture flasks that contained Dulbecco’s modified Eagle medium/Ham’s F-12 
medium, 10% FBS, and 1% antibiotic-antimycotic agent, and allowed to proliferate until 
the population reached confluency.  During this time, media changes were made every 3 
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to 4 d.  To purify the resulting mixed glia culture upon confluency, cultures were shaken 
overnight in an incubator to remove non-adherent cells.  Two cycles of treatment with the 
selective replication inhibitor cytosine arabinoside were carried out subsequently to 
further purify the astrocytic population.
Circles of aligned and random matrices were placed into 10-mm diameter culture 
wells and seeded with enzymatically dissociated astrocytes at a concentration of 104 
cells/ml.  Cultures were incubated for 7 d in the astrocyte media described above and 
fixed using 4% paraformaldehyde.  Following fixation, astrocyte cultures were 
immunostained for the astrocytic marker, glial fibrillary acidic protein (GFAP) (DAKO). 
Cultures were incubated for 2 h in a 1:1000 dilution of the GFAP rabbit primary antibody 
in PBS and visualized with a 1:200 dilution of Alexa Fluor 568 goat anti-rabbit secondary 
antibodies (Invitrogen) in PBS.  Images of astrocytes grown on aligned and random 
matrices were obtained with a Leica TCS-SP2 AOBS confocal microscope.  For this 
study, astrocytes were seeded on at least six matrices (three aligned and three random) 
and the experiment repeated at least three times.
Astrocytes-Dorsal Root Ganglia Co-culture
To test the extent to which astrocytes affect the growth of DRG neurites on 
electrospun PDS matrices, DRGs were co-cultured with astrocytes that were first seeded 
on matrices as outlined above.  Specifically, astrocytes were grown on either aligned or 
random matrices for 10 d until confluent.  DRGs were then pipetted onto these astrocyte-
seeded matrices, pinned down and cultured for an additional 10 days.
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Immunocytochemistry was performed using a primary antibody cocktail of GFAP 
and TuJ1, and confocal images obtained for analysis.  To determine the length of DRG 
neuritic outgrowth on aligned matrices with and without astrocytes, a distance 
measurement was made from the center of the DRG to the furthest extent of overall 
neuritic outgrowth.  Student’s t-test was used to determine statistical significance.  For 
this study, astrocytes and DRGs were seeded and pinned respectively on at least six 
matrices (three aligned and three random) and the experiment repeated at least three 
times.
Results
Using the apparatus shown in Figure 2.1, PDS was electrospun onto a mandrel 
with a rotation speed of either 5000 rpm or approximately 10 rpm to fabricate matrices 
containing fibers with varying degrees of alignment.  SEM was then used to visualize the 
extent to which a mandrel speed of 5000 rpm generates aligned fibers (aligned matrix) 
and a mandrel speed of approximately 10 rpm generates randomly orientated fibers 
(random matrix).  Although the difference in fiber alignment between the two types of 
matrices was evident at the SEM level (Figure 2.2A and D), a more objective 
determination of alignment was desirable to establish whether fiber alignment was 
significantly different.  To achieve this, we employed a 2D FFT methodology.  Such an 
approach quantitatively analyzes the extent to which the population of fibers in the matrix 
is aligned with respect to each other, thereby establishing a general direction of alignment 
of the entire fiber population.  After executing the algorithm on a converted grayscale 
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SEM image cropped down to a square (Figure 2.2A and D), the immediate output of a 2D 
FFT is a frequency spectrum (Figure 2.2B and E). The distribution of the pixels in the 
frequency spectrum can be used to evaluate fiber alignment in an original data image.  A 
data image containing random elements produces a frequency spectrum with pixels 
distributed about the center in a symmetrical distribution (Figure 2.2B). Conversely, a 
data image containing aligned elements produces a frequency spectrum with pixels 
distributed in an elongated ellipse (Figure 2.2E).  Figure 2.2C and F are graphs of a 2D 
FFT analysis on representative images of a random and aligned matrix, respectively.  The 
height and width of the peaks indicate the uniformity of fiber alignment.  The axis of 
distribution of the pixels in the frequency spectrum reports the principal axis of 
orientation (Ayres et al., 2006, 2008).  Fibers electrospun at a high mandrel speed were 
displayed graphically as having a dominant orientation toward a specific direction 
(approximately 180°, or a vertical orientation, in this case), thereby indicating a 
significant degree of alignment for the general fiber population.  In contrast, for a random 
matrix, the presence of four small symmetrical peaks (associated with edge artifact) 
indicates that there is no preferential alignment.  Moreover, the degree of fiber alignment 
in both types of matrices is consistent between electrospun samples fabricated for this 
study and those used in subsequent experiments.
After confirming the matrix alignment, DRGs were pinned to matrices, cultured 
for 10 d, fixed and immunolabeled for the TuJ1 neuronal marker.  Representative, low-
power, fluorescent images of the DRGs on aligned and random matrices showed different 
patterns of neuritic outgrowth (Figure 2.3).  On a random matrix, neurites grew radially 
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outward from the ganglion without preference to any specific direction, generating a 
round, spokes-of-a-wheel appearance (Figure 2.3A).  In contrast, on an aligned matrix, 
most neurites grew preferentially along a particular axis (Figure 2.3B).  Using reflectance 
confocal microscopy, it was confirmed that this axis of growth was in the same 
orientation as the underlying fibers of the matrix (data not shown).  Although a few 
neurites were not oriented initially to the direction of the underlying matrix, most 
eventually turned and continued their extension in the direction of the underlying fibers. 
Additionally, neurites growing in the direction of the underlying matrix grew faster than 
those growing perpendicular to the aligned fiber axis or on random matrix.
An observation that is not apparent in these images but evident in cultures grown 
for extended periods is that neurites began to show signs of cellular deterioration, such as 
the presence of membrane blebbing and vesiculation (Figure 2.6A).  These changes are 
common in neurons grown in vitro for extended periods in the absence of supportive or 
ECM substrata.  Considering this and the fact that the matrices are generated from a 
resorbable material (PDS) that dissolves with time, we hypothesized that a glial substrate 
might provide a more stable, supportive interface between the resorbable matrix and the 
outgrowing neurites.  Accordingly, astrocytes purified from P3 rat cortices were seeded 
onto aligned and random matrices and grown for 7 d.  Subsequently, the matrices were 
fixed and immunolabeled for the astrocytic marker GFAP.  Confocal images of astrocytes 
grown on both types of matrices show that these cells grew readily on electrospun PDS 
(Figure 2.4).  However, astrocytes grown on a random matrix extend processes that are 
positioned more randomly (Figure 2.4A and C). This is in striking contrast to astrocytes 
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grown on an aligned matrix (Figure 2.4B and C), for which process extension mirrors the 
orientation of the underlying fibers.
To test the extent to which astrocytes might improve the growth of DRG neurites 
on electrospun PDS matrices, DRGs were grown on matrices pre-seeded with astrocytes. 
First, dissociated astrocytes were seeded on aligned and random matrices and incubated 
for 10 d before DRGs were pinned onto the astrocyte-seeded matrices and incubated for 
10 d.  Subsequently, the matrices were fixed and dual-immunolabeled for TuJ1 and 
GFAP.  Following 20 d of growth, astrocytes seeded on both matrices extended longer 
processes than after only 7 d of growth (Figure 2.5A and C).  Moreover, astrocytic 
processes were aligned to match the orientation of the underlying PDS fibers within each 
matrix, which is consistent with a shorter culture period.  DRGs grown on a substrate of 
randomly-oriented astrocytes grew radially outward from the ganglion without preference 
to any specific direction (Figure 2.5A and B).  Conversely, DRGs grown on a substrate of 
aligned astrocytes (Figure 2.5C and D) displayed a similar alignment and extended longer 
processes than when grown on a glia-free matrix (Figure 2.5F).  Many of the neurites on 
the aligned, astrocyte-seeded matrices reached the border of the matrix and continued 
growing on its opposite side.  In both cases (aligned and random), processes changed 
direction readily to grow along astrocytic processes (Figure 2.5E). Moreover, DRGs 
grown on either seeded matrix displayed less fasciculated outgrowth than observed on 
PDS matrices alone and appeared to be more robust, as evidenced by the lack of 
vesiculations and membrane blebbing (Figure 2.6).
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Discussion
In this study, we have examined the potential use of electrospinning to engineer a 
polarized matrix for axonal guidance.  By varying the rate of rotation of the mandrel, 
matrices containing aligned fibers and randomly oriented fibers were fabricated from 
PDS.  The degree of fiber alignment was determined visually by SEM and quantified by 
2D FFT analysis.  Both neurons and astrocytes were grown separately and in combination 
on these matrices to assess biocompatibility and growth dynamics.  Specifically, when 
E16 DRGs were placed on these matrices and allowed to grow for 10 d, the direction of 
the projecting neurites matched the orientation of the underlying PDS fiber population. 
Moreover, on aligned matrices, the length of neuritic outgrowth exceeded that seen on 
random matrices.  After 10 d in culture, however, neurites began to exhibit evidence of 
necrosis.  In view of this, we tested the extent to which cortical astrocytes are compatible 
with these matrices and whether their presence affects DRG growth.  When seeded on 
these PDS matrices, astrocytes grew robustly and the orientation of process outgrowth 
matched that of the underlying matrix.  When DRGs were grown on these glial 
substrates, they exhibited no evidence of necrosis and their neurites aligned with 
astrocytes and displayed longer process outgrowth than on aligned PDS matrix alone. 
Collectively, these experiments demonstrate the potential for electrospinning to generate 
an aligned matrix that influences both the directionality and dynamics of DRG neuritic 
growth.
In addition to generating an aligned matrix to influence the directionality of 
neuritic outgrowth, the process of electrospinning can be manipulated further to generate 
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matrices with additional characteristics that mimic more closely the in vivo environment 
of the central nervous system (CNS).  Specifically, ECM molecules such as collagen and 
elastin remain biologically active when electrospun into matrices (Boland et al., 2004). 
These experiments provide evidence that viable ECM molecules in the CNS can also be 
electrospun into matrices to influence neuritic outgrowth.  In our study, however, we 
elected to use the synthetic molecule PDS as the solute for electrospinning because of its 
proven biocompatibility, which is indicated by its inability to elicit an immune response, 
and its structural stability in biological tissue.  These characteristics prevent the matrix 
from being remodeled in a manner that compromises its fiber polarity within a short time 
frame, which is relevant when considering the use of this matrix to bridge lesioned areas 
of the CNS.  Specifically, the alignment of the fibers in the matrix will remain stable, 
allowing regenerating axons sufficient time to cross the lesion into healthy target tissue. 
Moreover, by seeding the PDS matrix with astrocytes, we have generated a cellular 
bridge that retains alignment stability while providing crucial trophic support.  In the next 
two chapters, further modifications to the electrospinning process to generate a scaffold 
that may be able to counter the inhibitory compounds seen after SCI as well as the testing 
of these superior matrices are discussed.
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Figure 2.1.  The electrospinning apparatus.  Key system components include a solution 
reservoir (syringe), nozzle (18-gauge, blunted, metallic needle), high-voltage DC power 
supply, and grounded target (rotating mandrel).
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Figure 2.2.  Generation of aligned and randomly oriented PDS matrix fibers.  (A) SEM 
shows more randomly oriented fibers in a representative random matrix, generated by 
using a slower mandrel rotation speed (approximately 10 rpm).  (B) Raw output of the 2D 
FFT alignment analysis of a random matrix.  The more radially symmetrical silhouette of 
the 2D FFT is consistent with fibers that are oriented in random directions.  (C) Radial 
plot of the summations of relative pixel intensity at a radius versus the angle (°).  The 
periodicity of the graph is caused by the inherent symmetry of the raw 2D FFT output. 
The smaller, broader peaks reflect a more random distribution of directionality.  (D) SEM 
showing more consistently oriented fibers in a representative aligned matrix that is 
generated using a mandrel rotation speed of 5000 rpm.  (E) Raw output of the 2D FFT 
alignment analysis of an aligned matrix.  The slender profile of the silhouette indicates 
fiber alignment.  (F) A taller, narrower peak at approximately 180° indicates the general 
direction in which the fiber population is oriented.  Scale bars (A and B) = 10 µm.
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Figure 2.3.  Fiber alignment of the electrospun matrix is conferred to pinned DRGs. 
Low-power, wide-field, fluorescent image of a representative DRG immunostained for 
TuJ1 (green) on matrix fixed 10 d after pinning.  (A) DRG on a random matrix fixed 10 d 
after pinning.  DRG neurites grown on a random matrix displayed a tortuous growth 
pattern that reflects the underlying matrix.  (B) In contrast to DRG grown on a random 
matrix, neurites grew preferentially in one direction (vertical in this image) that reflects 
the orientation of the underlying matrix fibers.  Scale bars (A and B) = 200 µm.
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Figure 2.4.  Fiber alignment of the matrix is conferred onto seeded astrocytes.  Confocal 
images of astrocytes, immunostained with GFAP (red), grown on a random (A) or 
aligned matrix (B) for 7 d after seeding.  In both instances, the orientation of the 
underlying matrix fibers is conferred to the astrocytic processes.  (C) The average peak 
value of the 2D FFT analysis (radial plot) on astrocytes seeded on matrices.  Astrocytic 
process alignment on random and aligned matrices is statistically different (p = 0.004). 
Scale bars (A and B) = 100 µm.
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Figure 2.5.  Aligned astrocytes influence the directionality and length of DRG neuritic 
outgrowth (A to D).  Confocal images showing DRG neurites (green) grown on 
astrocytes (red) seeded on either random (A and B) or aligned (C and D) matrices.  In the 
presence of randomly oriented astrocytes (B), the orientation of the neurites is radial, 
growing out from the ganglion in all directions, whereas neurites grown on an aligned 
astrocyte-seeded matrix (D) display a similar alignment.  (E) High-power, wide-field, 
fluorescent image showing that neurites change direction to grow along astrocytic 
processes.  (F) The length of DRG neuritic outgrowth on aligned matrices with or without 
seeded astrocytes.  Outgrowth is significantly longer (p = 0.008) when grown on 
astrocyte-seeded matrices.  Scale bars (A to D) = 100 µm.  Scale bar (E) = 30 µm.
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Figure 2.6.  DRGs on astrocyte-seeded matrices grew more robustly, as evidenced by 
lack of vesiculation and fasciculation.  DRGs grown for 10 days on (A) a PDS matrix 
alone in the absence of astrocytes and (B) on an astrocyte-seeded PDS matrix. 
Astrocytes cannot be visualized because of the filter selection for this fluorescent image. 
Scale bars (A and B) = 10 µm.
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Chapter 3
Evaluating the Incorporation of Nerve Growth Factor and 
Chondroitinase ABC into an Electrospun Scaffold by Utilizing 
an Alginate Delivery System
Introduction
One of the many obstacles to spinal cord injury (SCI) repair following trauma is 
the formation of a cyst that impedes axonal regeneration.  Accordingly, as described in 
the previous chapter, we examined the potential use of electrospinning to engineer an 
implantable polarized matrix for axonal guidance.  Briefly, in a series of in vitro studies, 
we found that matrix alignment can be conferred to extending neurites, demonstrating the 
potential for electrospinning to generate an aligned matrix that can be implanted into the 
cyst so as to guide regenerating axons post-SCI.
However, many other obstacles hinder axonal regrowth in addition to the cyst.  As 
previously described, astrocytes within the SCI lesion site proliferate, hypertrophy, and 
begin to express chondroitin sulfate proteoglycans (CSPG), which represent potent 
inhibitors to axonal regeneration.  At the neuronal level, axotomy of motor and sensory 
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neurons results in the loss of neurotrophic support by target tissue, furthering the extent 
of neuronal cell death.  Additionally, the presence of myelin debris, as a result of 
oligodendrocyte death, acts as a potent inhibitor to axonal regeneration.  Collectively, 
these cellular responses to SCI represent major impediments to axonal regeneration. 
Mono-therapies that address each of these obstacles to regeneration individually have 
resulted in only limited axonal regrowth and functional recovery.  To date, no single 
intervention has been devised to collectively address all of these obstacles to regeneration 
after SCI.
In view of this, we hypothesized that our previously tested electrospun matrix can 
be supplemented with compounds that can promote neuronal survival and neutralize the 
growth-inhibitory proteins associated with gliotic scar.  One crucial criterion for 
optimizing axonal regeneration following SCI is to promote the survival of neurons 
whose axons have been severed.  It is well-known that neurotrophic factors are produced 
in the central nervous system (CNS) following trauma (Dougherty et al., 2000; Krenz and 
Weaver, 2000).  Their presence mitigates injury-induced neuronal cell death and 
promotes axonal plasticity and regeneration (Bregman et al., 1999; Zhou et al., 2003). 
Furthermore, both in vitro and in vivo studies have begun to establish the extent to which 
particular trophic factors stimulate axonal regeneration of the varying descending motor 
tracts and ascending sensory systems of the spinal cord.  For example, one particular 
neurotrophic factor, nerve growth factor (NGF), is essential for the growth and survival 
of several populations of sensory neurons that project axons through the spinal cord 
(Tuszynski et al., 1994; Acosta et al., 2001).  Accordingly, in a series of in vitro dorsal 
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root ganglion (DRG) bioassays, NGF was incorporated into electrospun matrices with the 
use of an alginate delivery system and the extent to which NGF remains bioactive was 
assessed.
In addition, we sought to investigate the extent to which we could incorporate 
other proteins into the matrix that could facilitate axonal regeneration.  Specifically, it is 
well-documented that following CNS injury astrocytes become reactive and begin to 
express CSPGs, which are well-known inhibitors to axonal regrowth.  Many in vitro and 
in vivo studies have established that the enzyme chondroitinase ABC (ChABC) is capable 
of inactivating the inhibitory functions of these proteins.  Accordingly, in another series 
of in vitro bioassays, ChABC was incorporated into electrospun and the extent to which 
the enzyme remains bioactive was assessed.
Materials and Methods
Generation of Alginate Microspheres
Found in the cell walls of certain brown algae and seaweeds, alginate is a viscous 
gum that is used in many industrial, food processing, and biomedical applications as a 
waterproofing, thickening, or detoxification agent.  Its apparent ease of gelation and 
biocompatibility can be exploited, providing a delivery vehicle for NGF in our study. 
Specifically, almost any protein of interest can be encapsulated in alginate microspheres 
and dried and upon hydration, release their content in a sustained manner (Noushi et al., 
2005).
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Alginate microspheres were generated by electrospraying technique.  A solution 
of 0.05-mg/ml sodium alginate and 0.05-mg/ml protease-free bovine serum albumin 
(BSA) (used as a carrier) was first produced and subsequently the solute of interest in the 
quantity of interest was added to 1 ml of this solution.  The solution was then loaded into 
a 5-ml syringe tipped with an 18-gauge blunt-end needle (Kontes) and the syringe 
installed onto a vertically mounted syringe driver such that the needle was pointed down 
(Figure 3.1).  The needle was connected to the anode of a high voltage direct current 
(DC) power supply (Spellman CZE1000R) via a wire outfitted with an alligator clip.  A 
metal plate, which was connected to the cathode, was placed beneath the syringe driver. 
A 150-mm glass Petri dish filled with 2% calcium chloride solution was placed on the 
metal plate to facilitate collection of the alginate microsphere.  Upon switching on the 
power supply, the resulting electric field induced the formation of a fine aerosol mist of 
alginate and upon contact with the calcium chloride solution, microsphere formation 
takes place.  Microspheres were collected and washed by centrifugation in a 2% calcium 
chloride solution supplement with 10% isopropanol and finally pelleted and the supernate 
removed.  To further dry the alginate, the remaining sediment is diluted 1:4 in 
1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) by volume and the mixture is placed in a 
syringe.  At this point, the HFIP, being the densest liquid in the mixture will settle to the 
bottom and it is subsequently dispensed, leaving the semi-dry alginate microspheres in an 
interface layer just above.  After dispensing the bulk of the HFIP, the tri-layered mixture 
is deposited in another container and by way of yet another syringe and fine hypodermic 
needle, the bottommost and topmost layers are removed to a greatest extent possible 
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without disturbing the middle layer containing the microspheres.  Finally, the remaining 
middle layer is frozen in liquid nitrogen and subsequently lyophilized.  The alginate is 
ready for use after rehydration.
Although the collection rate is incredibly difficult to measure and a 100% 
collection cannot be assumed, it is estimated that conservatively that we collect at least 
50% of the microspheres that can potentially form.  With that in mind, 5 µg of NGF 
(Invitrogen) was incorporated into the alginate microspheres such that when 
microspheres were allocated to individual cultures, the amount of NGF contained in the 
microspheres would have the same order of magnitude as compared to the amount 
contained in DRG culture media.  In contrast, control microspheres were generated with 
5 µg of protease-free BSA.
Dorsal Root Ganglia Isolation
DRGs were isolated from embryonic day 16 (E16) Sprague Dawley embryos as 
described previously in Chapter 2.  Briefly, embryos were removed from the uterus of a 
gravid rat and dissected open anteriorly to expose the developing spinal cord.  The entire 
cord was then dissected free from its rostral end and placed in Leibovitz L-15 media with 
10% fetal bovine serum (FBS).  The attached DRGs were then plucked off with fine tip 
forceps.
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Nerve Growth Factor Bioassay
To test the effectiveness of using alginate to deliver NGF, dissected DRGs were 
placed into poly-L-lysine-coated wells of a 48-well plate.  Each batch of alginate 
microspheres were rehydrated in culture media.  Assuming 50% collection, as previously 
discussed, a volume of media containing a desired quantity of NGF, which is 
incorporated in the microspheres, can be calculated.  After ensuring a uniform 
distribution of the microspheres, a calculated volume containing microspheres having a 
desired quantity of NGF that would ultimately provide a concentration of 0.3 µg/ml in the 
culture was transferred into Transwell membrane inserts and the inserts were placed in 
wells containing DRGs.  In normal DRG culturing conditions, a concentration of 0.1 
µg/ml is used.  Since the microspheres do not release their contents all at once, a higher 
starting concentration was desired.  Microspheres containing BSA were similarly 
deployed to act as controls.  Incubation media consisted of Eagle’s minimum essential 
medium with glutamine supplemented with 10% glucose and 5% FBS.  Additional 
negative and positive controls were set up by incubating DRGs with NGF-free and NGF-
containing media, respectively.  A schematic of the experimental setup is shown in 
Figure 3.3.  This assay was performed three times per animal with populations of E16 rat 
DRGs from four different animals.
To visualize the DRGs, the cultures were first fixed in 4% paraformaldehyde and 
subsequently immunolabeled for the β-tubulin neuronal marker TuJ1 (Covance) as 
previously described in Chapter 2.
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To quantify the extent of growth exhibited by the DRG cultures, the area occupied 
by the DRG neuritic processes was measured.  Wide-field fluorescence images of the 
DRGs were obtained and loaded into Adobe Photoshop.  Using the “contrast” tool, the 
contrast of the image is increased such that the colored pixels depicting neuritic processes 
reach maximum color intensity.  These pixels were then counted and since each pixel has 
an equivalent area, an actual area can be estimated without bias.
Electrospinning
As before, polydioxanone (PDS) was again used to fabricate matrices in this 
study.  However, instead of using a rotating grounded mandrel, an air-gap electrospinning 
system was adopted.  Air-gap electrospinning utilizes two separate fixed grounded posts 
in which the solution jet whips back and forth between the grounds, resulting in the 
deposition of fibers between the posts.  The rationale for migrating to this system is that 
this methodology offers superior fiber alignment.  In addition, this system allows for the 
spinning of 3-dimensional cylinders, which is required when these matrices are ultimately 
tested in animal models of SCI.
Briefly, for each matrix, a PDS filament was dissolved in the solvent HFIP at a 
concentration of 125 mg/ml and the solution was deposited in a syringe, which was 
mounted onto a syringe driver set to deliver 5 ml/hr.  Though the exact placements of the 
various electrospinning components differed between runs and required a bit of trial and 
error for the optimal positioning of the two grounded posts, generally the air gap between 
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posts was set between 3 to 5 cm and the assembly containing the posts was placed no 
more than 20 cm away from the nozzle.
Chondroitinase ABC Bioassay
To test the extent to which ChABC remains bioactive when the enzyme is 
electrospun into matrix directly, a stripe bioassay was employed.  Aggrecan, a CSPG 
known to inhibit axonal growth (Lemons et al., 2003), was deposited in stripe lane 
fashion via a micropipette onto poly-L-lysine-coated Thermanox cover slips.  Upon the 
drying of the aggrecan, DRGs were pinned onto the cover slips between the CSPG lanes 
and the cover slips were placed in Petri dishes containing NGF-added DRG culture media 
(formula described previously).  ChABC (0.5 U per matrix) was mixed into the PDS 
spinning solution and matrices were fabricated.  After spinning, these matrices were cut 
into small pieces such that each piece contained enough ChABC to supply a 
concentration of 0.05 U/ml in culture conditions.  After sterilizing in 70% ethanol, a 
piece of the cut ChABC-containing matrix was placed in each experimental dish while a 
piece of the cut BSA-containing matrix was placed in each control dish.  A schematic of 
the experimental setup is shown in Figure 3.5.  This assay was performed three times per 
animal with populations of E16 rat DRGs from four different animals.
To visualize the DRGs and aggrecan lanes, the cultures were first fixed in 4% 
paraformaldehyde and subsequently immunolabeled for the β-tubulin neuronal marker 
TuJ1 (Covance) and the CSPG marker CS-56 (Sigma).  In addition to the staining steps 
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outlined in Chapter 2, a denaturing step utilizing 2-M hydrochloric acid is included 
before blocking.
Results
Once we established that electrospinning can be used to generate a biocompatible 
bridge that provides directionality to axonal regrowth (Chapter 2), we next sought to 
establish the extent to which proteins that facilitate regeneration can be incorporated into 
the bridging matrix.  First, we sought to supplement the matrices with a neurotrophin, 
namely NGF, via the use of an alginate delivery vehicle.  NGF-containing alginate 
microspheres of uniform diameter were produced via electrospraying (Figure 3.2).  To 
test the effectiveness of using alginate to deliver NGF and the extent to which the 
neurotrophin remains bioactive, DRGs, which are a clusters of neurons that convey 
sensory information through the spinal cord and require NGF for their survival, were 
cultured in wells of a 48-well plate under the following conditions: in the absence of 
NGF in the media, in the presence of NGF in the media, in the presence of BSA-
containing microspheres, and in the presence of NGF-containing microspheres. 
Following 3 d of incubation, DRG neurites displayed predictably scant outgrowth in the 
absence of NGF (Figure 3.3B).  In the presence of NGF in the culture media, neuritic 
outgrowth was also unsurprisingly evident (Figure 3.3D).  However, the NGF-induced 
neuritic outgrowth was even more pronounced in cultures where DRGs were exposed to 
NGF-containing alginate microspheres (Figure 3.3F).  The readily apparent difference in 
the extent of outgrowth between NGF in media and NGF supplied by the alginate is 
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likely the result of the gradual increase in concentration of NGF in the media with time. 
To quantify the extent of outgrowth exhibited by the DRG cultures, the area occupied by 
the neuritic processes of each DRG was measured by counting pixels of digital images. 
The group means of the estimated area occupied by a DRG are shown in Figure 3.4. 
Finally, electrospun PDS matrices containing NGF-incorporated alginate microspheres 
were fabricated and tested on DRG cultures and similar results were obtained (data not 
shown).
We next sought to investigate the extent to which we can incorporate other 
proteins of interest into the matrix that could facilitate axonal regeneration.  Specifically, 
as mentioned previously, ChABC has been shown in numerous occasions its ability to 
elicit improved axonal regrowth and in some cases functional recovery following SCI by 
neutralizing the inhibitory nature of CSPGs.  In view of its success, we sought to 
incorporate ChABC into electrospun matrices as another means of making the post-SCI 
microenvironment more growth permissive.  Since reactive astrogliosis and gliotic scar 
formation have a longer time horizon, there needs to be a somewhat delayed yet sustained 
release in order for ChABC to be useful.  Accordingly, it was decided that ChABC be 
incorporated directly into the PDS matrix during the electrospinning process.  To test the 
extent to which enzyme remains bioactive in the matrix, DRG neurons were cultured 
between lanes of aggrecan, a known CNS CSPG, and an appropriately sized piece of 
matrix incorporated with or without ChABC was placed in each culture.  Following 7 d 
of incubation, in the absence of the enzyme, DRG neurites avoided the aggrecan lanes 
thereby demonstrating the extent to which CSPGs can inhibit axonal growth (Figure 
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3.5B).  In contrast, DRGs grown in the presence of the enzyme, which is released from 
the matrix, displayed no inhibition and readily grew across the aggrecan lanes (Figure 
3.5D).  These results demonstrate that the enzyme is released from the matrix in a 
bioactive form and neutralizes the axon growth-inhibitory properties of CSPG.
Collectively, these studies point toward a novel approach by which a 
biocompatible scaffold can be implanted into the fluid-filled cyst post-SCI, providing 
regenerating axons with a directional path across the lesion site as well as trophic and 
inhibitor-neutralizing support in a single package.
Discussion
One of the many pathologic obstacles of spinal cord repair following contusive 
trauma is the formation of a fluid-filled cyst across which regenerating axons have to 
traverse in order to reinnervate their distal targets.  To this end, in Chapter 2, we 
examined and demonstrated the potential use of electrospinning to engineer an 
implantable directional matrix for axonal guidance.  In view of the recognition that 
successful SCI therapies require a multifaceted tactic, we proposed a novel approach of 
incorporating into electrospun guidance matrices pharmacologic agents that can promote 
neuronal survival and neutralize inhibitory molecules associated with the gliotic scar. 
Specifically, NGF was encapsulated into electrospun alginate microspheres and the 
extent to which this protein remains bioactive was assessed with DRG bioassays.  These 
microspheres were placed in Transwell membrane inserts over the ganglia so as to 
provide the only source of NGF in the culture.  Their presence supported vigorous 
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neuritic outgrowth in contrast to control microspheres containing only albumin.  The 
bioactivity of NGF was similarly preserved when NGF-containing microspheres were 
incorporated into electrospun matrices.  We next sought to investigate the incorporation 
of ChABC into the matrix as it has been previously shown that this enzyme can reduce 
the axonal growth-inhibition of various CSPG.  Stripes of aggrecan, a CSPG found in the 
CNS, were placed on cover slips with DRGs pinned in between the inhibitory lanes.  In 
control cultures, DRG neurites did not extend onto aggrecan lanes.  However, upon 
exposure of the cultures to ChABC-incorporated matrices, the growth-inhibitory nature 
of aggrecan was neutralized and neurites grew extensively across the stripes. 
Collectively, these experiments point toward a novel SCI therapeutic approach of 
generating electrospun scaffolds that can directionally guide axons across the lesion site 
while providing trophic and inhibitor-neutralizing support.
A remarkable observation that was made in the present study was the dramatic 
difference in the outgrowth pattern of DRGs when cultures were exposed to NGF in the 
media versus NGF in the alginate microspheres.  When DRGs were exposed to NGF in 
the culture media, the DRG displayed a growth that was prototypical—neurites grew 
radially and linearly outward from the ganglion and producing a round, spokes-of-a-
wheel appearance.  When DRGs were exposed to the alginate microspheres containing 
the NGF, the neurites similarly grew outward radially from the ganglion.  However, the 
appearance of the neuritic processes in this experimental perturbation was not linear, but 
highly branched.  In these cultures, nearly all the neuritic processes were seen to 
crisscross and overlap over and over at almost all locations occupied by the DRGs.  Thus, 
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in view of our attempt to measure the area occupied by the neuritic processes by way of 
counting pixels in high resolution digital images and our subsequent detection of 
quantitative differences in the amount of growth between experimental groups, we 
surmised that we probably still underestimated the extent of growth in the culture 
exposed to the alginate microspheres.  Since the amount of microspheres that was 
initially deposited in these experimental cultures was determined assuming a 50% 
collection estimate after electrospinning, it was first suggested that the dramatic 
outgrowth seen was perhaps due to a much higher concentration of NGF, which could 
have potentially reached at much as six times the level used in the positive control culture 
if the NGF was release all at once from the alginate.  As introduced in the first chapter, 
the low-affinity p75 neurotrophin receptor (p75NTR) may act as a sink for the excess 
NGF and synergizes with the tropomyosin receptor kinase (Trk) receptor, specifically 
TrkA, to produce the extraordinary branched pattern of DRG process outgrowth seen. 
However, in a side experiment where DRGs were exposed to 10µg/ml of NGF (ten times 
the normally used concentration), the branched pattern of outgrowth was not observed.  A 
second explanation is that perhaps the alginate may have some synergistic effect with the 
NGF.  Though no known mechanism would suggest that this would occur, we 
nevertheless tested this hypothesis in yet another side experiment where DRGs were 
exposed to NGF in the culture media while blank alginate microspheres were deposited 
in the cultures.  Again, only the typical radially linear outgrowth pattern was seen.  A 
third possibility that may cause the dramatic branching is that perhaps the neurons 
respond to a gradual increase in NGF concentration in the media from the alginate 
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release.  Such an increase of neurotrophin may result in a temporal shift of the cellular 
profile of activated receptors.  The p75NTR, having low affinity to the neurotrophins, 
would not bind the NGF early on during the experiment but would bind later when the 
NGF concentration in the media increased.  Though we did not attempt to prove this 
hypothesis, this explanation can be established with a simple experiment where DRGs 
would be exposed to a gradually increasing concentration of NGF.
Another notable observation involves the ChABC-CSPG stripe bioassays. 
Though DRG neurites undoubtedly grew over the aggrecan lanes when exposed to 
ChABC, the DRG processes displayed a webby fasciculated appearance.  As mentioned 
in Chapter 2, it is well-known that neurites often fasciculate when elongating on a less 
than optimal substrate and that cell adhesion molecules and their interactions with the 
substrate play a significant role in this response (Acheson et al., 1991; Honig and 
Rutishauser, 1996; Tang et al., 1994).  In an in vitro study, Snow et al. demonstrated how 
DRG neurites readily fasciculate upon contact with locales containing very low 
permissive concentrations of CSPGs, stayed fasciculated while elongating over such 
areas, and defasciculated upon leaving the CSPG zone (2003).  While ChABC was not 
employed in the study completed by Snow et al., their results show that even a minute 
amount of an inhibitor, though not able to outright prevent outgrowth over the inhibitory 
areas, was able to cause neuritic fasciculation.  In our study, ChABC cleaved the 
glycosaminoglycan chains on the aggrecan molecules, which is known to reduce the 
inhibitory nature of the CSPGs.  However, though less understood, there are also direct 
protein core effects, which may partially explain the fasciculation seen in our cultures. 
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Hence, in our study, while the ChABC is able to reduce the inhibition of the aggrecan 
such that outgrowth is possible on the CSPG lanes, the reduction is not enough to cause 
defasciculated growth.  Fasciculated growth is not necessary undesirable, as it has been 
suggested that fasciculation may promote axonal pathfinding and prevent deviant 
sprouting post-injury (Snow et al., 2003).
In the experiments outlined in this chapter, NGF was selected and tested in 
bioassays experiments.  However, the presence of NGF in the microenvironment post-
SCI has been shown to cause undesirable side effects such as autonomic dysreflexia and 
neuralgia caused by the aberrant spouting of certain neurons (Krenz et al., 1999). 
Autonomic dysreflexia is a condition characterized by an immense sympathetic discharge 
caused by noxious stimuli that results in increased blood pressure via widespread 
vasoconstriction.  Neuralgia, also known as neuropathic pain, is pain that is not a result of 
pain receptor activation.  Both of these adverse conditions are debilitating and potentially 
dangerous, with the former being a medical emergency.  In view of this, we seek to 
incorporate other factors into our matrices that may be beneficial post-SCI.  Since we 
have demonstrated that NGF can successfully be integrated into our matrices and 
delivered, other factors can be incorporated to aid in the survival and resprouting of other 
neuronal groups.  Exogenous administration of brain-derived neurotrophic factor (BDNF) 
and neurotrophin-3 (NT-3) have been found to preserve the neuroplasticity of 
corticofugal fibers and in some cases led to functional recovery post-SCI (Namiki et al., 
2000; Iarikov et al., 2007).  Additionally, insulin-like growth factor-1 (IGF-1), a 
polypeptide with sequence homology to insulin released primarily by the liver in 
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response to growth hormone that affects human cells almost ubiquitously, has been 
shown to promote the growth of projecting axons and dendrites, synaptogenesis, and 
neuroprotection (Niblock et al., 2000; Cheng et al., 2003; Ozdinler and Macklis, 2006; 
Hung et al., 2007).  Hence, these factors such as BDNF, NT-3, and IGF-1 can 
concomitantly be delivered via alginate microspheres by way of an electrospun matrix 
implant.
In other experiments outlined in this chapter, ChABC was selected to be 
incorporated into our electrospun matrices so as to neutralize the CSPGs seen after SCI. 
However, other axon growth-inhibitory molecules have also been identified.  One 
notorious group of inhibitors is found to be associated with central myelin.  Members of 
this group include Nogo-A, myelin-associated glycoprotein, and oligodendrocyte-myelin 
glycoprotein (McKerracher et al., 1994; Chen et al., 2000; Kottis et al., 2002).  All three 
have been demonstrated through in vitro and in vivo studies to cause growth cone 
collapse by their binding to the Nogo-66 receptor (Liu et al., 2002; Xie and Zheng, 2008). 
In view of this, we seek to incorporate a compound into our matrices that can overcome 
the inhibitory effects of these myelin-associated proteins.  One such compound of interest 
is bucladesine, which is a cell permeable cyclic adenosine monophosphate (cAMP) 
analog.  Also known as dibutyryl cAMP, this cyclic nucleotide has been shown to alter 
the growth state of older neurons and induce axonal growth in the presence of myelin-
associated inhibitors (Cai et al., 1999; Gao et al., 2003; Domeniconi and Filbin, 2005). 
Accordingly, bucladesine is an excellent candidate for incorporation.
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Figure 3.1.  The electrospraying apparatus is very similar to the electrospinning 
apparatus.  Key system components include a solution reservoir (syringe), nozzle (18-
gauge, blunted, metallic needle), high-voltage DC power supply, and grounded target.
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Figure 3.2.  (A) A light microscopic image of alginate microspheres showing their 
uniform diameter.  (B) A wide-field fluorescence image of the same microspheres 
showing the incorporation of a fluorescent protein.  The white arrows point to the same 
piece of debris, indicating the same field of view in both images.  Scale Bars (A and B) = 
10 μm.
75
76
Figure 3.3.  Bioassay assessing the bioactivity of NGF-incorporated alginate 
microspheres on DRG outgrowth.  DRGs were isolated from E16 rat embryos and 
cultured in wells of a 48-well plate.  Schematics (A, C, and E) of the experimental setup 
and their corresponding results (B, D, and F) are shown.  In the absence of NGF in the 
media (A), predictably no outgrowth is seen (B).  However in a positive control setup, 
specifically in the presence of NGF in the media (C), neuritic outgrowth is evident (D). 
Microspheres were deposited in a Transwell insert and placed into wells (E).  Neuritic 
processes of DRGs exposed to NGF-incorporated alginate microspheres showed 
exuberant outgrowth as compared with the positive control (F).  Scale Bars (B, D, and F) 
= 500 μm.
77
00.005
0.01
0.015
0.02
0.025
0.03
M edia without NGF M edia with NGF BSA Microspheres NGF M icros pheres
Experimental Conditions
A
re
a 
O
cc
up
ie
d 
by
 N
eu
rit
ic
 P
ro
ce
ss
es
 (m
m
2 )
78
Figure 3.4.  The extent of outgrowth exhibited by the DRG cultures when exposed to 
various sources of NGF (in media or alginate microspheres) was quantified and shown 
here.  The difference in the extent of outgrowth between NGF in media and NGF 
supplied by the alginate is likely the result of the gradual increase in concentration of 
NGF in the media with time.
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Figure 3.5.  Stripe bioassay of dorsal root ganglia (green) grown between aggrecan lanes 
(red) for 7 d in culture.  Aggrecan, a CSPG, is a known inhibitor of axonal regrowth 
following SCI.  Schematics of the stripe bioassays are shown with or without 
incorporating ChABC into the matrix (A and C) and their corresponding results (B and 
D).  In the absence of ChABC, DRG neurites were inhibited from growing on aggrecan 
lanes (A and B).  In contrast, in the presence of a ChABC-incorporated matrix, the 
growth-inhibitory nature of aggrecan was neutralized.  Aggrecan lane boundaries marked 
by arrows.  Scale Bars (B and D) = 500 μm.
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Chapter 4
Preliminary Tests of Implanting Electrospun Matrices in a Rat 
Spinal Cord Transection Model
Introduction
In Chapter 2, we presented data demonstrating the successful use of 
electrospinning to generate biocompatible, implantable matrices that are able to direct 
neuritic outgrowth.  And in Chapter 3, we showed how these matrices can be enhanced to 
address the two specific therapeutic obstacles of neurotrophic support and increased 
chondroitin sulfate proteoglycan (CSPG) expression after spinal cord injuries (SCI) by 
supplementing the matrices with a growth factor and an enzyme that neutralizes the axon 
growth-inhibitory activity of CSPGs.  In view of these successes, we next sought to 
examine the extent to which these matrices perform when implanted into a rat model of 
SCI.  In this brief chapter, we present a bit of preliminary results showing some initial 
successes of this in vivo study.
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Materials and Methods
Electrospinning
Air-gap electrospinning was similarly employed in order to fabricate cylindrical 
conduits of aligned fibers as described previously in Chapter 3 and the suture material 
polydioxanone (PDS) was again used.  Briefly, for each matrix, a PDS filament was 
dissolved in the solvent HFIP at a concentration of 125 mg/ml and the solution was 
deposited in a syringe, which was mounted onto a syringe driver set to deliver 5 ml/hr. 
Though the exact placements of the various electrospinning components differed between 
runs and required a bit of trial and error for the optimal positioning of the two grounded 
posts, generally the air gap between posts was set between 3 to 5 cm and the assembly 
containing the posts was placed no more than 20 cm away from the nozzle.  To match the 
size of the thoracic cord in a rat, spinning continued until a diameter target of 2 mm was 
reached during the fabrication process.
Animal Model and Surgical Procedures
Adult Long Evans Hooded rats aged approximately 70 days were used for this 
study.  Owing to extensive experience with the rat percussive SCI model, we learned that 
the presentations of cystic cavities that formed post-injury were highly inconsistent. 
Furthermore, the extent of white matter sparing was equally variable.  Therefore, in this 
study, we elected not to use the percussive SCI model.  Though we hope that these 
electrospun matrices would in the future be used to bridge the fluid-filled cyst after 
contusion SCIs in humans, we wanted an experimental animal model that would present 
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consistent complete injuries so that our testing conditions of these electrospun matrix 
implants would be as uniform as possible from animal to animal.  Accordingly, a 
transection SCI model was selected instead.
Adult Long Evans Hooded rats aged approximately 70 d were used for the 
transection SCI protocols.  All surgical and postoperative care procedures were 
performed in accordance with the Virginia Commonwealth University Institutional 
Animal Care and Use Committee.  Animals were placed in a closed container, sedated 
with 5% isoflurane, endotracheally intubated, and maintained under 2.5% isoflurane 
during surgical procedure.  Depth of anesthesia was assessed periodically during the 
surgical procedures by tail pinch and watching for reflexive movements.  Body 
temperature was kept normothermic using a homeothermic blanket placed under the 
animal.  Employing sterile techniques, a dorsal midline incision was made over the mid-
thoracic spine and a standard thoracic level 8 (T8) laminectomy was performed on the 
animal to expose the spinal cord (Figure 4.1A).  A 2-mm segment of the cord was then 
completely removed via transection by iridectomy scissors, leaving a similarly sized gap 
(Figure 4.1B).  Thrombin-soaked foam pieces were placed in and around the created gap 
to hasten hemostasis.  After bleeding slowed (usually after about 15 to 20 min post-
transection), an electrospun PDS matrix conduit was custom-fitted into the gap and 
approximated to the cut cord stubs such that the fiber grain of the matrix ran 
longitudinally with the cord (Figure 4.1C).  The wound was closed in layers with silk 
sutures and skin incision closed with surgical staple clips.  Animals were subsequently 
allowed to recover in a separate area containing a warming blanket.  
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All animals received prophylactic gentamicin (5 mg/kg) before surgery and daily 
thereafter for 7 d.  Post-operatively, all animals were given easy access to food and water 
and housed two per cage.  Analgesic medication (acetaminophen oral suspension, 2 
mg/ml) was mixed into the drinking water and administered for the first 3 d post-injury. 
Manual bladder expression was performed three times daily for the first week after 
surgery and two times daily thereafter until spontaneous micturation was reestablished. 
Due to the severe nature of transection cord injuries, spontaneous micturation generally 
did not occur in animals until the eighth week post-surgery.
Preliminary Results
At the end of week 1 and week 6 post-surgery, animals were sacrificed and their 
spinal cord containing the electrospun implant was isolated.  Grossly, the implant was 
well integrated into the cord with excellent implant-stub adherence (Figure 4.2A).  These 
cords were cryosectioned longitudinally and the sections were labeled with the cell 
nuclear fluorescent stain DAPI (4’,6-diamidino-2-phenylindole).  At the end of week 1 
post-surgery, growing tissue has enveloped the implant and cells are seen infiltrating the 
implant from all sides (Figure 4.2B).  By week 6 post-surgery, the matrix implant is 
almost packed full of cells (Figure 4.2C).  These results demonstrate the biocompatibility 
and the capacity of the electrospun matrix conduit to facilitate cellular infiltration, an 
important step in the bridging of gaps and cysts post-SCI.  We are currently carrying out 
other histological and behavioral assessment experiments to determine the extent of 
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implant penetration by regrowing axons and recovery of motor functions.  For these 
experiments, enhanced matrices such as those described in Chapter 3 are being tested.
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Figure 4.1.  Photographs showing the matrix implantation portion of the surgical 
procedure.  (A) The spinal cord (arrow) is exposed after completing a laminectomy at the 
T8 level.  (B) A gap (arrow) remains after 2 mm of the cord is removed via transection. 
(C) Placement of a similarly sized cylinder of electrospun matrix (arrow) into the gap.
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Figure 4.2.  (A) Gross view at week 6 post-surgery of a transected cord implanted with 
an electrospun matrix conduit.  (B) A representative longitudinal cord section labeled 
with a fluorescent cell nuclear marker DAPI showing excellent integration of the matrix 
(arrows) into the cord by the end of week 1 post-surgery.  Cells are seen infiltrating the 
matrix from all sides.  (C) By week 6 post-surgery, the matrix (arrows) is almost packed 
full of cells.  Scale Bars (A) = 2 mm.  Scale Bars (B and C) = 500 µm.
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Chapter 5
Chronicling the Injury-Induced Proliferative Response at the 
Spinal Cord Injury Lesion Site and Attenuating the Response 
with X-Irradiation
Introduction
Traumatic injury to the spinal cord results in the proliferation of cells at the lesion 
site that mature into astrocytes, ultimately resulting in the formation of a gliotic scar.  The 
cells within the scar, of which the majority are astroctyes, express factors that are known 
to inhibit axonal regeneration.  In addition, as a result of the tight spatial cellular 
associations of the scar, regrowing axons are prevented from crossing the scar toward the 
opposite margin of the lesion.  Consequently, the scar presents both a biochemical and to 
a lesser extent physical barrier to axonal regeneration following spinal cord injury (SCI). 
It is believed that the attenuation of this injury-induced cell population may be helpful in 
reducing the inhibitory nature of the scar so as to allow a greater extent of regeneration 
(Moon and Fawcett, 2001; Woerly et al., 2004; Tian et al., 2006).  Furthermore, gliotic 
scar attenuation may be a necessary adjuvant treatment to the implantation of a bridging 
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scaffold since the scar represents on-ramp and off-ramp barriers to axonal regrowth onto 
and off of the bridge.  The attenuation of cellular proliferation needs not be extreme, 
since, as previously noted, the gliotic scar features a number of important beneficial 
effects, such as the isolation of damaged tissue from viable tissue and its notable role in 
providing a substrate for angiogenesis.
Accordingly, using a rat percussive cord injury model and employing 
immunohistochemical and flow cytometric methods by means of various cellular 
proliferation and glial cell markers, we first identified the injury-induced cell populations 
in and around the SCI lesion site and subsequently chronicled their initial periods of 
proliferation.  Once this information was obtained, we next sought to demonstrate the 
extent to which this proliferative response can be attenuated with methods that target 
dividing cells.  Specifically, as previously shown by this laboratory and others, cellular 
proliferation can be attenuated by appropriate levels of ionizing irradiation, a very similar 
procedure which has been applied for decades to control malignant cells in cancer 
therapy.  Irradiation therapy possesses a number of desirable characteristics in that it is 
non-invasive, reproducible, and accurate in its targeting.  The use of irradiation as an 
adjunctive therapy for SCI is not entirely novel.  A very small number of published 
studies have previously demonstrated mixed results in attenuating scar formation and 
improving motor function (Kalderon et al., 2001; Pinjuh and Bedi, 2003; Ridet et al., 
2000; Zeman et al., 2001; Zhang et al., 2005).  A reason for the inconclusiveness of these 
studies perhaps may be attributable to the irradiation dosing, which was sometimes orders 
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of magnitude apart between studies.  Furthermore, the timing and frequency of doses 
given often varied greatly between methodologies.
In view of these apparent deficiencies, a serial series of related experiments was 
completed systematically so that the best timing and dose can be determined.  As 
previously stated, a chronicling of the injury-induced proliferative response after SCI was 
first accomplished.  This was done to establish the timing component.  Before initiating 
the irradiation experiments, exhaustive dosimetry was completed with the assistance of 
the Division of Radiation Physics and Biology in the Department of Radiology.  In order 
to obtain dosing response and efficacy in neural tissue, the irradiation method was first 
tested on a model of normal cellular proliferation in neural tissue, namely the 
subventricular zone (SVZ) of neonatal rats, which contains a large number of dividing 
cells.  Later, the paradigm was further tested on an injury-induced cellular population in a 
cortical stab injury rat model before ultimately tested on a contusion SCI rat model.
Materials and Methods
Mixed Glia Isolation and Culture
Before proceeding to in vivo experimentation, the reliability of employing flow 
cytometry to count glial cells required confirmation.  In view of this, unpurified glial 
cultures were first used to test the flow cytometric methodology.  In accordance with the 
Virginia Commonwealth University Institutional Animal Care and Use Committee, glial 
cells were isolated using similar methods described previously (McCarthy and de Vellis, 
1980).  Briefly, isolated postnatal-day 3 rat cortices were minced and dissociated 
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mechanically and enzymatically.  Cells were seeded into T-75 poly-L-lysine-coated 
tissue culture flasks that contained Dulbecco’s modified Eagle medium/Ham’s F-12 
medium with 10% fetal bovine serum and 1% antibiotic-antimycotic agent, and allowed 
to proliferate until the population reached confluency.  During this time, culture media 
changes were made every 3 to 4 d.  Cultures were ready for use after splitting.
Flow Cytometry
Flow cytometric methods were carried out using similar procedures described 
previously (Bilsland et al., 2006).  Glial cultures were trypsinized, resuspended, fixed 
with 4% paraformaldehyde, and permeabilized with Cytoperm (BD Biosciences).  Cells 
were first labeled with 7-aminoactinomycin D (7-AAD) to identify cells from debris and 
subsequently labeled with fluorochrome-conjugated antibodies for the thymidine analog 
and marker of proliferating cells bromodeoxyuridine (BrdU) and for the glial markers 
vimentin and glial fibrillary acidic protein (GFAP).  Negative control antibodies were 
used to facilitate the setting of quadrant gates.
Animal Model and Surgical Procedures
Adult Long Evans Hooded rats aged approximately 70 d were used for the 
contusion SCI protocols.  All surgical and postoperative care procedures were performed 
in accordance with the Virginia Commonwealth University Institutional Animal Care and 
Use Committee.  Animals were endotracheally intubated and maintained under inhalation 
anesthesia (2.5 % isoflurane) during surgical procedure.  Depth of anesthesia was 
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assessed during surgical procedures by tail pinch and observation for reflexive 
movements.  Body temperature was kept normothermic using a homeothermic blanket. 
Employing sterile techniques, a dorsal midline incision was made over the mid-thoracic 
spine and a standard thoracic level 8 (T8) laminectomy was performed (Figure 5.1B). 
Animals were then placed in a spinal frame and the exposed spinal cord was contused 
with the Multicenter Animal Spinal Cord Injury Study (MASCIS) impactor using a 10-g 
weight dropped from a height of 25 mm (Figure 5.1A and 2.1C).  Sham animals 
underwent laminectomy but did not receive spinal cord contusions.  The reproducibility 
of the computer-driven MASCIS impactor can be assessed by examining the impact 
parameters acquired by the computer during each trial, which includes the trajectory of 
the falling rod, impact velocity, cord compression distance, and cord compression time. 
Animal injuries with unacceptable impact parameters were excluded entirely from the 
study.  The wound was closed in layers with sutures and skin incision closed with 
surgical staple clips.  Animals were subsequently allowed to recover in a separate area 
containing a warming blanket.  For the irradiation studies, the impact site location was 
noted via a single exclusive suture tied through skin and muscle layers dorsal to the 
laminectomy site.
All animals received prophylactic gentamicin (5 mg/kg) before surgery and daily 
thereafter for 7 d.  Post-operatively, all animals were given easy access to food and water 
and housed two per cage.  Analgesic medication (acetaminophen oral suspension, 2 
mg/ml) was mixed into the drinking water and administered for the first 3 d post-injury. 
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Manual bladder expression was performed three times daily for the first week after 
surgery and two times daily thereafter until spontaneous micturation was reestablished.
Chronicling the Glial Cell Proliferation at Lesion Site
To establish the time course of the injury-induced proliferative response after SCI 
and relate this to gliotic scar formation, animals were first divided into two groups of 
sham and injured.  Subsequently, they were subdivided further (n = 3) as to the day post-
injury (day 1, 2, 3, 4, 7, 10, and 14) an animal would receive two doses, 12 h apart, of 
BrdU (300 mg/kg body weight).  On day 14 post-injury, animals were sacrificed with a 
lethal dose of pentobarbital and transcardially perfused with phosphate buffered saline 
(PBS).  The 5-mm spinal cord segment containing the SCI lesion epicenter was harvested 
and the tissue was mechanically dissociated by passage though a 70-µm filter.  The 
resulting cell suspension was washed with PBS and the unwanted erythrocytes were lysed 
with tris-buffered ammonium chloride.  The cells were then prepared as described 
previously for flow cytometric analysis.
X-Irradiation
To assess the extent to which X-irradiation can attenuate the normal proliferative 
response in neural tissue, the SVZ of neonatal rats, which is an area in the brain 
containing large numbers of dividing cells, was unilaterally irradiated via a Faxitron 
43855D X-ray irradiator with varying single doses (5, 10, 15, and 20 Gy).  (Irradiator 
dosimetry was completed with film before experiments proceeded.)  When it was 
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determined that 15 Gy was the lowest dose that can attenuate 80% of the proliferative 
response (data not shown) as compared to the SVZ of the control hemisphere, the use of 
irradiation was further explored in injury-induced cellular proliferation model, 
specifically in a cortical stab injury in rats.
After determining the peak period of proliferation via the chronicling experiment 
described above, another group of SCI animals (n = 3) received a single dose of 
irradiation administered on day 2 post-injury.  To prepare the animal for the irradiation 
procedure, the rat was first anesthetized with a mild dose of ketamine/xylazine cocktail 
and placed in a small box.  The dorsum of the animal was raised with a paper towel roll 
placed beneath its upper abdomen.  To protect the other tissues for irradiation damage, a 
2-mm thick solid lead plate containing a square opening of 2.5 cm by 2.5 cm was placed 
over the animal, with the center of the opening aligned with the laminectomy site as 
noted by an exclusive suture that was tied during the wound closure after surgery.  The 
box containing the animal was then placed into the irradiator and a dose of 15 Gy as 
determined by the duration of exposure (about 14 min) administered.  After the exposure, 
the animal was allowed to recover.
Results
Though the ultimate goal is to examine the approach of using X-irradiation to 
reduce gliotic scar formation after SCI, a series of experiment was planned to determine 
the appropriate dose and timing of the therapy.  In order to establish the appropriate dose 
of the irradiation, various doses were first tested on a model of normal cellular 
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proliferation in neural tissue.  Based on previous experience of the procedure in our 
laboratory (McGinn et al., 2008), four different doses of irradiation (5, 10, 15, and 20 Gy) 
were tested on the SVZ of neonatal rats, which contains a large number of dividing cells. 
It was found that 15 Gy sufficiently attenuated the proliferative response by 80% (data 
not shown).  Subsequently, the use of irradiation was further tested on an injury-induced 
cellular proliferation model, specifically a cortical stab injury in rats.  In this experiment, 
rats were given a needle stab injury to the cortex, inducing the cells in the vicinity to 
proliferate (Figure 5.2A).  In contrast, rats that were then irradiated at the site of injury 
when cells began to proliferate at day 2 post-injury showed the presence of only few 
dividing cells (Figure 5.2B).
Now that the dosing of irradiation was established, we wished to explore when 
such a dose should be given to maximize its effect.  In the next series of experiments, we 
sought to establish the time course of the injury-induced proliferative response in SCI and 
relate this to gliotic scar formation with the use of flow cytometry.  In order to ascertain 
the validity of using flow cytometry to count cells of the central nervous system (CNS), a 
preliminary study using mixed glial cultures was first completed (Figure 5.3).  When it 
was found that flow cytometry can reliably count vimentin+ and GFAP+ cells, the 
chronicling of the injury-induced proliferative response with in vivo experiments 
proceeded (Figure 5.4).  For reactive astrocytes, which are labeled with vimentin, the 
peak period of proliferation lasts from day 2 to 5 post-injury (Figure 5.4G).  We then 
found that a single targeted 15-Gy exposure of irradiation to the lesion site at day 2 post-
injury reduced the proliferating cell population by over 50 % (Figure 5.4H).
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Discussion
We hypothesized that irradiation treatment, when targeted to the site of spinal 
cord trauma, may reduce the injury-induced proliferative cell population.  As this 
population contributes significantly to the formation of the gliotic scar, the reduction of 
this cell population would reduce scar formation and create a more favorable 
environment for axonal regeneration.  However, since the gliotic scar contributes a 
number of important benefits, we merely want to “punch a few holes” such that 
regrowing axons can penetrate the physical barrier aspect of the scar while scar integrity 
can be preserved to prevent the spread of cellular destruction.  To optimize the process, 
we completed several preliminary experiments in order to determine the lowest dose that 
can be used to maximally attenuate the injury-induced proliferative response as well as 
the best timeframe for administration.
In this study, though we showed how irradiation can attenuate the injury-induced 
proliferative response post-SCI, we never proceeded to determine the extent to which 
irradiation can improve functional outcome.  In the past several years, there has been 
increasingly strong evidence that the reactive astrogliotic process and subsequent gliotic 
scarring play an imperative role in neuroprotection during the early acute phase of injury. 
As discussed previously, it has been known for some time that the scar possesses a 
beneficial role, especially in the establishment of a new glia limitans around the lesion. 
However, mounting evidence as to the scar being inhibitory to regeneration has led to the 
common general perception that it is something that should aggressively be removed or at 
least reduced in size even though earlier evidence has shown scar ablation to drastically 
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increase lesion volume and promote neuronal and oligodendrocyte cell death (Bush et al., 
1999; Fauklner et al., 2004).  In view of the many recent studies that show how the gliotic 
scar goes beyond just isolating the lesion post-injury, specifically the roles of sealing the 
blood-brain barrier, preventing overwhelming inflammatory infiltration, supplying 
various growth factors, and even promoting axonal sprouting (Okada et al., 2006; 
Renault-Mihara et al. 2008; Rolls et al., 2009), the overall perception of the scar being 
unfavorable post-SCI is slowly changing.
Though it is still true that the scar represents a barrier to regeneration, both 
physically and biochemically, this recent paradigm shift of regarding gliotic scar 
formation as almost necessary during the immediate and acute phases of injury leads us 
to reconsider the advantages of attenuating the injury-induced cellular proliferation so 
early on post-SCI.  However, once the SCI lesion is stabilized and the process of gliosis 
occurred to such an extent that the scar causes more harm than benefits, we believe the 
continuing injury-induced proliferation, despite having peaked earlier, can still be 
attenuated by way of irradiation to facilitate a more efficient penetration of regrowing 
axons into and beyond the gliotic scar.
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Figure 5.1.  (A) The MASCIS Impactor, developed in 1991 by Drs. John Gruner, Carl 
Mason, and Wise Young, is a device used to deliver reproducible spinal cord contusions 
in rats.  A 10-g rod can be dropped onto an exposed rodent spinal cord from a distance of 
12.5, 25, or 50 mm, which equate approximately to a mild, moderate, or severe contusion 
SCI respectively.  (B) The white spinal cord is exposed after completing a laminectomy 
at the vertebral level T8.  (C) The spinal frame holds the animal via two spinous 
processes adjacent to the laminectomy so that the exposed segment of the cord is aligned 
directly beneath the rod.
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Figure 5.2.  A single dose of irradiation can drastically reduce the number of 
proliferating cells in the injured cortex.  (A) Sections immunolabeled with BrdU (green) 
and GFAP (red) showing the injury-induced proliferative response 4 d following a 
cortical stab wound (arrow).  (B) The reduction of this response as a result of a single 
dose of irradiation directed locally at the wound site 2 d post-injury.
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Figure 5.3.  Flow cytometry can reliably count vimentin+ and GFAP+ cells.  Unpurified 
glial cultures were trypsinized, resuspended, fixed, and permeabilized.  Cells were first 
labeled with 7-AAD to identify cells from debris (A) and subsequently labeled with 
fluorochrome-conjugated antibodies for BrdU, vimentin, and GFAP.  Negative control 
antibodies were used to facilitate the setting of quadrant gates for the BrdU-vimentin 
analysis (B) and BrdU-GFAP analysis (C).  Flow cytometric counts (F and G) were 
comparable to that of actual counts done on immunolabeled cultures (D and E).  A 
similar study was also completed using glioblastoma cells and cell counts using all three 
markers were equally comparable between flow cytometric and manual 
immunocytochemical counts (Data not shown).
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Figure 5.4.  Spinal cords of rats were percussively injured by a 10-g weight drop from 25 
mm.  To obtain the flow cytometric dataset displayed here, on day 4 post-injury, animals 
were given two doses of BrdU.  On day 14 post-injury, the 5-mm spinal cord segments 
containing the lesion epicenter from three experimental groups of rat (sham, injured, and 
injured with irradiation) were mechanically dissociated into a cell suspension, fixed, and 
permeabilized.  Cells were first labeled with 7-AAD to identify cells from debris (A) and 
subsequently labeled with fluorochrome-conjugated antibodies for BrdU and vimentin. 
To facilitate the setting of quadrant gates for the analysis, cells from the spinal cord of a 
non-BrdU treated sham animal were used (B).  In sham animals, very little proliferation 
was seen as shown by BrdU immunohistochemistry (C) and as indicated by low flow 
cytometric counts of BrdU+ events in the top two quadrants (1.0% + 2.1%) (E).  In 
contrast, in injured animals, there is a massive increase of cell proliferation as shown by 
BrdU immunohistochemistry (D) and flow cytometry (4.6% + 19.0%) (F).  Moreover, a 
large number of these proliferating cells are vimentin+ (19.0%).  The above described 
process was repeated with BrdU being administered at different time points and a graph 
depicting the chronicling of the proliferative response of vimentin- and GFAP+ cells was 
generated (G).  A single dose of irradiation administered at the beginning of the peak 
period of proliferation (day 2 post-injury) was able to attenuate the injury-induced 
proliferative response as indicated by flow cytometry (H).  Scale Bar (C) = 1 mm.
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Chapter 6
Concluding Statement
Traumatic spinal cord injury (SCI) is a debilitating, costly, and emotionally 
devastating condition that is characterized by marked neuropathology and limited 
recovery of function.  While the initial insult rapidly disrupts neural tracts and kills cells, 
an insidious, complex secondary cascade of cellular and biochemical events soon 
follows.  Glial cells such as astrocytes react to the injury by proliferating and 
hypertrophying, which results in the development of a gliotic scar that partitions the 
lesion epicenter from viable tissue.  Although this process aids to prevent the spread of 
uncontrolled tissue damage, the scar nevertheless acts as a physical barrier to axonal 
regeneration.  Furthermore, the scar and the cells within are a major source of axon 
growth-inhibitory molecules such as chondroitin sulfate proteoglycans (CSPG) and thus 
concomitantly acts as a biochemical barrier.  Concurrently, inflammatory cells infiltrate 
the cord parenchyma and through immunologic activation, possess the capacity to 
exacerbate damage by propelling viable cells into apoptosis.  Additionally, the severing 
of axons results in the interference of neurotrophic support, making neuronal survival 
precarious.  Finally, the pathology culminates in the formation of a fluid-filled cyst, 
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which puts in place yet another insuperable hurdle for regrowing axons to overcome. 
Collectively, these pathological processes perhaps partially explain the lack of effective 
central nervous system (CNS) recovery seen following SCI.
Up until the recent decades, there was little hope for the successful treatment of 
SCI.  But despite our incomplete understanding of the mechanisms that control these 
pathological processes, we now know that they are amenable to therapeutic interventions 
that may promote neuroplasticity and the regeneration of axons, leading to improved 
functional outcomes.  Moreover, it has been demonstrated numerous times that adult 
CNS neurons retains the ability of regrowing functional axons (Richardson et al., 1980; 
von Meyenburg et al., 1998; Chuckowree et al., 2004).  In view of this, when provided 
with a permissive microenvironment, the notion of severed axons regenerating is indeed a 
very valid possibility.
In this dissertation, we introduced a few of our own strategies to overcome the 
aforementioned therapeutic challenges post-SCI.  We employed electrospinning to 
generate a biocompatible matrix implant that can bridge and direct axonal elongation 
across the fluid-filled cyst.  Given the complex array and scope of pathological sequelae 
post-SCI, it is generally recognized that successful treatment requires a multifaceted 
approach.  In view of this, we presented novel approaches by which successful tried and 
true therapeutic strategies are combined.  To facilitate the delayed but necessary long-
term release of an enzyme capable of neutralizing the axon growth-inhibitory activity of 
CSPGs, chondroitinase ABC was incorporated directly into our electrospun matrices and 
tested.  And to ensure an immediate replacement source of neurotrophic support during 
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the acute phase of the injury, we tested the use of an alginate microsphere vehicle that 
can also be incorporated into our electrospun matrices to deliver growth factors and other 
potential neuroprotective and growth-promoting agents.  To address the injury-induced 
proliferative response, which represents an on-ramp off-ramp obstacle that prevents 
axonal regeneration onto our matrix implant, we showed how X-irradiation can moderate 
the the injury-induced proliferative glial response so as to facilitate a more efficient 
penetration of regrowing axons into and beyond the gliotic scar.  And finally, FTY720 
was utilized as a pharmacologic intervention to prevent lymphocytic egress from 
lymphoid tissues and reducing the infiltration of lymphocytes into the cord parenchyma 
post-SCI, which resulted in improved hindlimb motor recovery.
Although many of the ideas presented have been assessed in animal studies and 
these experiments have produced results that demonstrated potential and optimism, these 
strategies may not translate easily into human SCIs without additional effort.  As 
mentioned previously, the presentation of cysts formed post-SCI is highly variable in 
both its time of emergence and spatial dimensions.  While the timeframes of the many 
cellular and molecular events have been chronicled in the rodent models of SCI, 
researchers have only a rudimentary understanding of such details in human cases of 
SCIs due to the sparse availability of study specimens.  A determination of the 
appropriate time to implant our or any other experimental scaffold bridges post-SCI in 
humans will be required to optimize regeneration.  Additionally, while cavities formed 
post-injury in human SCIs are inherently larger than those of rat SCIs, fitting, aligning, 
and implanting our bridging matrices into these narrow cysts may not be trivial. 
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Although extreme, some have suggested transecting and removing the damaged cord 
segment in contusion SCI patients that have absolute complete cord injuries and replacing 
the segment with a bridge in a process similar to our animal trials.  There is some merit 
with this radical procedure since much of the inhibition and barrier effects are removed 
instantly.  Additionally, a laceration of the cord, such as this method, has been shown to 
produce little gliotic scarring, which would enable the cord stubs to act as a more 
permissive on-ramp off-ramp zone after bridge implantation.  Naturally, this approach 
would not be a therapeutic solution for incomplete SCI patients with cords that have 
some level of white matter sparing.
Another notion of interest is the use of our electrospun matrix implants during the 
chronic phase of human SCI, which generally begins six months to a year after the initial 
traumatic insult.  Although research targeting the chronic phase of the injury is sorely 
lacking, what is known is rather discouraging.  In a longstanding injury, the diminished 
regenerative capacity of the neurons and the increasing rigid scar barriers at and beyond 
the lesion site make functional recovery even more of a challenge.  Potential therapies 
that have shown promise when applied acutely, have almost all shown to fail when 
employed to injuries older than four weeks in animal models of SCI (Houle and Tessler, 
2003).  At this point with our current understanding, it is most likely that the best 
therapeutic time window will reside during the early stages of the injury’s pathological 
progression.
Table 6.1 displays a general but almost exhaustive list of therapeutic obstacles 
arranged by the timeframes in which they occur after traumatic SCI.  Each of these 
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phases presents a number of known therapeutic aims.  A combination of treatments that 
target in a serial fashion the listed objectives during the appropriate timeframe would 
probably give SCI patients the best chance at regenerating axotomized neurons and 
recovering lost physiological functions.  Despite this well-recognized point of view, very 
few combinatory strategies have been documented in the literature.  This is not surprising 
given the difficulty of the problem and the enormous amount of resources required to 
carry out experiments based on a combinatory approach.  Nevertheless, in the short span 
of four years, we came up with a few novel ideas, tested them experimentally, and have 
started to combine some of these potential treatment strategies.  As discussed in Chapter 
5, we have now obtained some promising preliminary results from our matrix implant 
trials in animals.  Though more in vivo runs are required to show conclusively that our 
electrospun matrix is able to bring about functional improvements post-SCI, we plan to 
combine our other treatment approaches as well as other outside strategies that have been 
proven to be successful.
Collectively, the ideas presented in this manuscript and the results from 
experimentally testing these ideas represent a new body of knowledge that, if perhaps 
only incrementally, advance the pathological understanding as well as the treatment of 
traumatic SCI.
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SCI phases, timeframe of phases, key events, and therapeutic aims within each phase
Phases Immediate Phase Acute Phase Subacute Phase Intermediate Phase Chronic Phase
Approximate 
Timeframe
in
Human
Injuries
Immediately to Hours
after injury
Hours to days
after injury
Days to weeks
after injury
Weeks to months
after injury
Months to years
after injury
Events 
and
Potential 
Therapeutic 
Obstacles
 Primary 
mechanical 
insult
 Severing 
of axons
 Hyperemia
 Blood 
vessel damage 
and hemorrhage
 Microglial 
activation
 Edema
 Ischemia 
and hypoxia
 Hemorrha
gic necrosis
 Excitotoxi
city
 Blood-
spinal cord 
barrier 
degradation
 Demyelina
tion
 Inflammat
ory infiltration
 Reactive 
astrogliosis
 Gliotic 
scarring
 Cyst 
formation
 Wallerian 
degeneration
Major
Therapeutic
Goals
Within
Phase
 Neuroprot
ection and 
promotion of 
neuronal 
survival
 Immune 
modulation
 Modulatio
n of injury-
induced 
proliferation
 Promotion 
of regeneration
 Remyelina
tion
 Neutralizat
ion of myelin 
debris and 
proteins
 Neutralizat
ion of 
proteoglycans
 Cyst 
bridging
 Physical 
Rehabilitation
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Table 6.1.  The aftermath of SCI is divided into five phases: the immediate phase, acute 
phase, subacute phase, intermediate phase, and chronic phase.
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Appendix
FTY720 Reduces Inflammation and Promotes Functional 
Recovery after Spinal Cord Injury
Introduction
The pathophysiology of spinal cord injury (SCI) has classically been partitioned 
into primary and secondary injury processes.  As described previously, after the initial 
primary injury, secondary injury encompasses an insidious cascade of cellular and 
biochemical events, the magnitude of which is rivaled only by its complexity.  Within 
this milieu of events, inflammation has been identified as an important component of 
secondary injury and numerous cell populations have been implicated as mediators of 
inflammation.  Among these cells, lymphocytes have generated interest for their key 
involvement in the concept of trauma induced autoimmunity (Popovich et al., 1996; 
Gonzalez et al., 2003; Ankeny et al., 2006).  This concept is based on the hypothesis that 
traumatic injury results in the release of neural self-antigens and subsequent immunologic 
activation.   In support of this possibility, injection into naïve animals of T cells isolated 
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from rats subjected to SCI resulted in central nervous system (CNS) tissue injury and 
neurological deficit (Popovich et al., 1996).
Many of these studies in SCI and autoimmunity have drawn on parallels from our 
current knowledge of multiple sclerosis (MS) and the animal model experimental 
autoimmune encephalomyelitis (EAE).  In both of these processes, T cells are known to 
infiltrate the CNS, resulting in demyelination and neurologic dysfunction.  Targeted 
therapies for MS have therefore focused on immunomodulation, specifically in the T cell 
population.
Fingolimod administration is one of the newest immunomodulatory therapies for 
MS and is currently undergoing phase III clinical trials as a monotherapy.  Fingolimod, 
commonly known as FTY720, is a chemical derivative of the fungal metabolite myriocin 
and in its phosphorylated form, acts as a spingosine-1-phosphate (S1P) mimetic and 
agonist of the S1P receptor (Brinkmann et al., 2002).  Several groups have shown that 
administration of FTY720 results in a significant reduction in peripheral lymphocyte 
counts (Chiba et al., 1998; Brinkmann et al., 2000; Pinschewer et al., 2000).  It has been 
postulated that FTY720 induces this lymphopenia by preventing lymphocyte egress from 
peripheral lymphoid organs.  Once FTY720 binds to the S1P receptor, internalization and 
subsequent degradation of the receptor occurs (Matloubian et al., 2004).  This 
degradation thereby eliminates the necessary S1P signal for lymphocyte egress and 
prevents recirculation into the CNS (Brinkmann et al., 2002; Mandala et. al., 2002; 
Matloubian et al., 2004).
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Independent of this ability to prevent lymphocyte migration, FTY720 has also 
been shown to have other cytoprotective capabilities.  Studies have shown that FTY720 
can prevent apoptosis in neural cells and act on endothelial cells to preserve vascular 
integrity (Fujino et al., 2003; Brinkmann et al., 2004; Coelho et al., 2007).  The exact 
mechanisms of these effects are still under investigation.
In the series of experiments presented in this chapter, we examined the efficacy of 
FTY720 in a moderate to severe contusion model of SCI.  We hypothesized that 
administration of FTY720 would reduce infiltration of T cells to the spinal cord lesion 
site and enhance functional recovery after SCI.  Our results indeed demonstrate the 
efficacy of FTY720 in a model of CNS trauma and show that administration enhances 
tissue preservation and functional outcome after SCI.
Materials and Methods
Animal Model and Surgical Procedures
Adult Long Evans Hooded rats aged approximately 70 days were used for the 
contusion SCI protocols.  The surgical procedure employed in this study was identical to 
that used in the previously discussed study of Chapter 5 and details of the method can be 
found in that chapter.
Immediately after injury, animals were randomized to receive an intraperitoneal 
injection of FTY720 (1 mg/kg body weight) (Cayman Chemical, Ann Arbor, MI) 
solubilized in 0.1% dimethyl sulfoxide (DMSO), vehicle (0.1% DMSO), or no injection 
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(injury only).  Animals were then allowed to recover in a separate area with a warming 
blanket.
All animals received prophylactic gentamicin (5 mg/kg body weight) before 
surgery and daily thereafter for 7 d.  Manual bladder expression was performed three 
times daily for the first week after surgery and two times daily thereafter until 
spontaneous micturation was reestablished.  Urine volumes were recorded at each 
collection and spontaneous micturation was defined as established when daily volumes 
collected were less than 2 ml total for 3 consecutive days.  Expressed urine was also 
monitored for evidence of urinary tract infection (UTI) by the presence of elevated urine 
pH or leukocytes and treated with a 5-d course of gentamicin if diagnosed.
Flow Cytometry
For flow cytometry, injured animals received daily intraperitoneal injections of 
either FTY720 (n = 5) or vehicle (n = 5) until sacrificed.  On the first, fourth, and seventh 
days post-injury, animals were sacrificed with a lethal dose of pentobarbital and perfused 
transcardially with phosphate buffered saline (PBS).  A 1-cm section of the cord centered 
to the impact site as well as the spleen was then harvested.  Both the cord and spleen 
tissue were individually dissociated by passage through a 70-µm filter and washed twice 
with PBS.  Erythrocytes were lysed with tris-buffered ammonium chloride.  Leukocytes 
were identified as round, phase-bright entities with a diameter of approximately 10 µm 
that excluded trypan blue and were enumerated on a hemocytometer.  Antibodies used for 
phenotypic analysis were anti-CD3, -CD4, -CD8α, -CD11b, and -His48 and were 
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biotinylated or conjugated to R-phycoerythrin or fluorescein isothiocyanate (BD 
Biosciences).  Streptavidin conjugated to allophycocyanin was used for the detection of 
biotinylated antibodies.  Approximately 1 × 106 cells were stained with 0.5 µg of each 
monoclonal antibody as previously described (Graf et al., 2001).  Cells were then fixed 
with Cytofix (BD Biosciences), permeablized with Cytoperm (BD Biosciences), washed 
with PBS, and stained with the DNA-specific dye 7-aminoactinomycin (7-AAD) at a 
concentration of 10 µg/ml.  Three-color fluorometric analysis was performed using a 
FACSCanto flow cytometer (BD Biosciences).  Cells were identified as 7-AAD+ events 
on a FL3 verses side scatter histogram as described by Lipton et al. (2005) and 10,000 7-
AAD+ events were analyzed.  T cell subsets were identified as CD3+/CD4+ or 
CD3+/CD8+ double-positive cells.  Monocytes and granulocytes were identified as 
CD11b+ and His48+ cells, respectively.
Behavioral Outcome Assessment
All animals were gentled in an open field twice a day for 7 consecutive days prior 
to injury.  Animals randomized to the treated group (n = 11) received daily 
intraperitoneal injections of FTY720 for 4 weeks.  Vehicle group animals (n = 10) 
received daily intraperitoneal injections of 0.1% DMSO for the same time period.  The 
injury only group (n = 9) received no injections.  Laminectomies were performed on 
sham animals (n = 2) but no cord injuries were performed and no injections administered. 
At day 2 and 7 post-injury and once weekly thereafter for a total of 6 weeks, rats were 
placed in the open field and observed for 4 min (Figure A.1A).  Two researchers blinded 
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to treatment groups observed the animals in open field testing.  Gross locomotor recovery 
after SCI was assessed using the Basso-Beattie-Bresnahan (BBB) locomotor rating scale 
as shown in Table 3.1 (Basso et al., 1995).  Observations for each hind limb were scored 
and averaged to provide a single score for each animal per session.  All data were 
collected within the 4 min period.  Once a plateau in locomotor recovery was evident 
(generally after day 28 post-injury), a frequency analysis of plantar stepping and 
coordination was performed across all groups.
All animals were also tested on the inclined plane task (Figure A.1B).  This task 
evaluates the animal’s ability to maintain a horizontal body position on an inclined board. 
The angle of the board is incrementally raised until the animal is no longer able to 
maintain the horizontal position.  Performance on the inclined plane correlates with the 
integrity of the rubrospinal tract (as well as other non-pyramidal pathways) after SCI. 
During testing, animals were placed in the right and left side up positions.  The maximum 
angle at which the animal was able to maintain position on the board for 10 s was 
recorded for each side.  Data were recorded as the average of the two sides to obtain a 
single score for each animal per session.
Analysis of Myelin Sparing
At week 6 post-injury, animals were sacrificed with a lethal dose of pentobarbital 
and perfused transcardially with PBS followed by 4% paraformaldehyde.  Spinal cords 
were harvested and postfixed for 2 h in the same fixative before being immersed in PBS 
overnight.  The fixed cords were then cryoprotected in 30% sucrose for 48 h.  FTY720-
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treated (n = 9) and vehicle (n = 8) cords were blocked and embedded together in optimal 
cutting temperature compound and sectioned at a thickness of 20 μm.  A complete series 
of axial sections spanning the injury site was collected and stained with eriochrome 
cyanine (EC) to assess for myelin sparing.  Also, axial sections peripheral to the injury 
epicenter were collected at 0.5-mm intervals and stained with EC.  For each spinal cord, 
the lesion epicenter was qualitatively defined by a blinded researcher as the section 
containing the least amount of intact tissue.  This section and sections located 100 μm 
rostral and caudal were chosen to quantify the area of spared myelin at the epicenter. 
Light microscopy at 25 × magnification was used to visualize the sections and images 
were captured with an Olympus DP12 camera.  These images were then imported into 
ImageJ, an open architecture image processing program developed at the National 
Institutes of Health, and white matter sparing analysis was performed by a blinded 
observer.  Percent myelin spared was calculated by manually outlining the spared white 
matter regions which then generated an area as denoted by the number of pixels.  This 
area was then divided by the total cross-sectional area of the axial section.  The average 
of the three sections was used to denote the percent myelin spared at the injury epicenter. 
In the same fashion as described above, sections rostral and caudal to the epicenter at 0.5-
mm intervals were analyzed for white matter sparing.
Statistical Analysis
The data presented here in this chapter is reported as means ± standard error of 
the mean.  All statistical analyses were performed using the statistical software package 
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SPSS.  Open field, inclined plane, and urine volumes data were analyzed by repeated 
measures two-way analysis of variance (ANOVA) with post hoc pairwise comparison 
test.  Days to spontaneous voiding data was analyzed by one-way ANOVA with post hoc 
Tukey analysis.  The Fisher’s exact test was used for hematuria incidence and locomotor 
frequency analysis.  Flow cytometry and myelin sparing analysis data were compared 
using Student’s t-test.  Differences with a p value less than 0.05 were considered 
statistically significant.
Results
FTY720 reduces T cell infiltration to the spinal cord lesion site after injury.
FTY720 is known to be a potent immunomodulator and numerous reports have 
shown that administration reduces peripheral lymphocyte circulation (Chiba et al., 1998; 
Brinkmann et al., 2000; Pinschewer et al., 2000).  In order to establish the efficacy of 
FTY720 treatment in a model of SCI, we quantified inflammatory cell infiltration into 
injured spinal cord using flow cytometry.  Data from this analysis showed that FTY720 
administration significantly reduced the infiltration of CD4+ T helper cells to the spinal 
cord lesion site as compared to vehicle administration at day 4 post-injury (7.56 ± 0.25 
vs. 3.80 ± 0.5, p < 0.001) (Figure A.2D).  This response was similar to the reduction seen 
in the CD8+ cytotoxic T cell population (7.80 ± 1.01 vs. 3.68 ± 1.31, p = 0.008).  At day 
7 post-injury, a similar reduction was seen in the CD4+ T helper cells (10.01 ± 1.40 vs. 
6.40 ± 0.72, p = 0.048) and in the CD8+ cytotoxic T cell population (8.51 ± 0.51 vs. 6.01 
± 0.40, p = 0.009).  However, there was no difference noted in either cell population at 
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day 1 post-injury.  For all time points, no statistical difference was noted between vehicle 
and FTY720 administration in the spleen tissue.
In order to evaluate for other inflammatory cell populations infiltrating the spinal 
cord after injury, antibody labeling for His48 (granulocytes) and CD11b (monocytes) was 
performed (data not shown).  A slight trend towards reduction was observed with 
FTY720 administration in the His48+ (24 ± 2.4 vs. 20.2 ± 1.9, p = 0.29) and the CD11b+ 
cell populations (40.3 ± 1.47 vs. 32.8 ± 7.5, p = 0.38).  However neither of these 
differences was statistically significant, suggesting that FTY720 specifically inhibits T 
cell infiltration.
FTY720 promotes hind limb recovery after spinal cord injury.
Once we established the efficacy of FTY720 in a model of SCI, our next step was 
to determine the extent to which administration would impact functional recovery.  Hind 
limb function was therefore evaluated for 6 weeks after injury using the open field and 
inclined plane tests.  During the acute and intermediate recovery stages, no differences in 
BBB locomotor scores were noted among groups (Figure A.3A).  However, by day 21 
post-injury the mean BBB score in the FTY720-treated animals surpassed those of the 
vehicle animals by 1.4 (11.5 vs. 10.1, p = 0.02).  Moreover, this difference was sustained 
throughout the remainder of the analysis even after drug treatment was discontinued at 
day 28 post-injury.  By the end of the analysis, the mean difference between treated and 
vehicle groups was 1.5 (12.5 vs. 11.0, p = 0.001).  No differences were noted between 
vehicle and injury only groups at any time point.
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A frequency analysis of the open field data is shown in Table 3.2 and reflects 
differences in locomotor milestones between the groups once recovery reached a plateau. 
For each time point analyzed, a significantly greater proportion of animals were 
consistently plantar stepping (BBB ≥ 11) or stepping with occasional coordination (BBB 
≥ 12) in the FTY720-treated group as compared to vehicle and injury only groups.  By 
day 42 post-injury, all animals in the FTY720-treated group were consistently plantar 
stepping and 81.8% exhibited at least occasional coordination.  In contrast, only 80% of 
animals in the vehicle group exhibited consistent plantar stepping and only 20% were at 
least occasionally coordinated.
Performance on the inclined plane mirrored open field testing performance with 
the exception that differences were noted at earlier times along the study (Figure A.3B). 
By day 14 post-injury, the mean difference between treated and vehicle groups was 6.5° 
(35.5 vs. 29, p < 0.0001).  Average angles were consistently higher in the treated group 
for the duration of the study and at day 42 post-injury the mean difference between 
treated and vehicle groups was 8.6° (43.9 vs. 35.3, p < 0.0001)  
For both the open field and inclined plane tests, no significant difference in scores 
was detectable at any time point between vehicle and injury only control groups.  Linear 
regression analysis revealed a very strong correlation (r = 0.87) between the BBB and 
inclined plane scores for all time points (Figure A.3C).
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FTY720 improves bladder function after spinal cord injury.
A well-known consequence of SCI in both animals and humans is bladder 
dysfunction.  Using an animal model of SCI, Wrathall et al. (2006) showed that injury 
severity could be directly correlated with degree of bladder dysfunction, which was 
reflected in the volume of urine collected during manual expression.  We therefore sought 
to utilize bladder function as another measure of functional recovery.  Figure A.4A shows 
that all animals had impaired bladder function immediately after SCI.  However, animals 
in the treated group had significantly lower mean urine volumes expressed as compared 
to vehicle and injury only groups (n = 10 for each group, p < 0.0001).  Post hoc analysis 
also revealed no statistical difference between vehicle and injury only groups in terms of 
daily urine volumes collected.
For all animals, daily bladder expressions were performed until total daily volume 
collected was less than 2 ml for 3 consecutive days, indicating return of spontaneous 
bladder function.  Inter-group comparison of the number of days required to reach this 
milestone revealed that animals in the treated group required fewer days as compared to 
vehicle and injury only groups (Figure A.4B) (6.2 ± 0.4 vs. 10.3 ± 0.6 and 9.8 ± 0.74, p < 
0.0001).  No statistical difference was noted between vehicle and injury only groups.
For each urine collection, urine color was recorded.  Retrospective analysis of the 
incidence of gross hematuria revealed that FTY720 treatment significantly reduced the 
incidence of gross hematuria as compared to vehicle and injury only groups (Figure 
A.4C) (45.5% vs. 90% and 100%, p = 0.002).  No difference was noted when comparing 
vehicle and injury only groups with each other.
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FTY720 and Body Weight
One important aspect of assessing the utility of an immunosuppressant drug is 
determining whether the drug has an unacceptable level of toxicity.  Many 
immunomodulators, although useful in their ability to reduce inflammation, are limited 
by their toxicity profile.  Animal body weight was used as an indicator of general toxicity 
and monitored throughout the course of the study.  Decreases in body weight can indicate 
failure to thrive which would then imply drug toxicity.  However, no significant 
differences in percent change in body weight were noted among the three treatment 
groups studied (Figure A.5).
Locomotor recovery correlates with myelin sparing.
In order to correlate locomotor recovery results with histological findings, we 
performed myelin sparing analysis of the lesion epicenter.  Animals were sacrificed at the 
end of the final open field testing and spinal cords were harvested for EC staining.  Due 
to the lack of differences detected in behavioral outcome between the vehicle and injury 
only groups, we confined our analysis to the treated (n = 9) and vehicle groups (n = 8) for 
comparison.  The data showed that FTY720 treatment resulted in a significant increase in 
the percentage of myelin spared (Figure A.6C) (28.5 ±1.6 vs. 20.8 ± 1.7, p = 0.004).  By 
linear regression analysis, final BBB scores also had a very strong correlation with 
percentage of myelin spared at the epicenter (Figure A.6D, r = 0.75).
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Discussion
The data presented in this study demonstrate that FTY720 administered after SCI 
dramatically reduces T cell infiltration into the spinal cord.  Furthermore, the results of 
behavioral outcome analyses revealed that treatment with FTY720 was effective in 
enhancing hind limb and bladder recovery.  Interestingly, the effect of FTY720 on hind 
limb function was evident during the chronic phase of recovery in contrast to its effect on 
bladder function which was noted during the acute recovery phase.  Results from 
morphometric analysis also provided support for the neuroprotective capacity of FTY720 
and revealed that white matter preservation is enhanced with treatment.
Our initial step in establishing the efficacy of FTY720 in SCI was to determine 
whether treatment would affect lymphocyte infiltration into the spinal cord after injury. 
Analysis by flow cytometry revealed that treatment with FTY720 after SCI significantly 
reduced T cell infiltration into the spinal cord whereas granulocyte and monocyte 
populations were relatively unaltered.  These data are in agreement with previously 
reported studies that showed that FTY720 had differential effects on CD4+ and CD8+ T 
cells and minimal effects on peripheral blood counts of granulocytes and monocytes 
(Quesniaux et al., 1999; Budde et al., 2003; Kahan et al., 2003; Bohler et al., 2004).  The 
degree of lymphocyte reduction has been shown to be dose-dependent but previously 
reported reduction ranges of 30 to 70% (Quesniaux et al., 1999; Bohler et al., 2004) are in 
good agreement with the data reported in this study of 50 to 59%.
Our flow cytometry results clearly demonstrated the efficacy of FTY720 as an 
immunomodulator in post-SCI inflammatory response.  However, the question remained 
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as to whether this would have a beneficial or detrimental effect on functional recovery. 
Although inflammation is a well-established sequela of CNS trauma, its role in recovery 
has been somewhat controversial.  Both beneficial and detrimental effects have been 
associated with the inflammatory process.  Through the release of cytokines and other 
factors, inflammatory cell populations such as neutrophils and macrophages have long 
been associated with CNS toxicity (Chao et al., 1992; Bao et al., 2002; Shamash et al., 
2002; Donnelly et al., 2008).  Various groups have further demonstrated that attenuation 
of these inflammatory mediators is beneficial and promotes neurologic recovery (Giulian 
et al., 1990; Blight, 1994; Popovich et al., 1999; Gris et al., 2004; Pannu et al., 2005; 
Beril et al., 2007).  However, it has also been suggested that inflammation may play a 
dual role in neural recovery and may have significant beneficial aspects.  As surveyors of 
the CNS, microglia have been hypothesized to have a clearing mechanism after spinal 
cord injury, eliminating debris and reducing the presence of any factors that might play 
an inhibitory role in CNS repair.  These cells are known for their cytotoxic capabilities 
but they have also been shown to secrete trophic factors for both neurons and glia (Banati 
and Graeber, 1994; Kreutzberg, 1996).  There is also evidence that macrophages may 
have a neuroprotective role in the CNS (Rimaniol et al., 2000; Yin et al., 2006).
The concept of protective autoimmunity has been championed by some with the 
implication that enhancement rather than attenuation of the immune response is necessary 
to promote CNS recovery (Schwartz and Kipnis, 2001, 2002; Yoles et al., 2001). 
Experimental data revealed that augmentation of the immune response via passive or 
active immunization with myelin basic protein limited secondary degeneration and 
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improved functional recovery after SCI (Hauben et al., 2000, 2001).  As a result, efforts 
have been made to design vaccines for various neurodegenerative diseases as well as for 
CNS trauma (Schwartz, 2001).  However, the concept of protective autoimmunity also 
runs counter to the classic concept of T cells as pathologic entities.  Using T cells isolated 
from spinal injured rats, Popovich et al. (1996) demonstrated that injection into naïve rats 
resulted in neurological deficit and pathology reminiscent of EAE.  Subsequent studies 
using transgenic mice and athymic nude rats also support the traditional view of the T 
cell as a pathogenic entity (Jones et al., 2002; Potas et al., 2006).   Interestingly, 
independent efforts to replicate the original experimental vaccine protocols of Hauben et 
al. (2000, 2001) failed to demonstrate any benefit and in fact revealed that functional 
recovery was impaired with vaccination (Jones et al., 2004).  This has raised some 
questions regarding the safety and utility of intentionally activating CNS-reactive T cells 
(Popovich and Jones, 2003; Jones et al., 2004).
It is clear therefore that the only conclusion that can be made regarding the 
inflammatory response is that it is quite complex and these studies only bolster the notion 
that the role of inflammation cannot be succinctly distilled as either beneficial or 
detrimental.  In this present study we showed that administration of FTY720 dramatically 
reduced T cell infiltration into the spinal cord lesion site and enhanced locomotor 
recovery as well as tissue preservation after SCI.  Although the locomotor enhancement 
observed in the open field and inclined plane tests was modest, frequency analysis of the 
open field data highlighted the differences between treatment groups.  By the end of the 
study, the vast majority of animals in the treated group exhibited at least occasional 
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coordination whereas only a minority of animals in the vehicle group exhibited this 
milestone.  Previously reported studies by Gonzales et al. (2003) using a mouse spinal 
hemisection model, also showed similar results after T cell infiltration was inhibited 
using a neutralizing antibody to a T cell chemoattractant chemokine.  Similarly, Ibarra et 
al. (2003) showed that pharmacologic inhibition of T cell responses to spinal cord 
antigens using cyclosporine improved functional recovery after SCI.
The results from this present study would then imply that the T cells attenuated by 
FTY720 are deleterious in the process of recovery.  Since FTY720 is not specific for all 
inflammatory cell populations, it may be that treatment is inhibitory to pathologic 
lymphocytic populations only and not to that subset which may have a beneficial role. 
However, it is clear that the mechanism of action of FTY720 is not solely limited to 
immunomodulation.  In vitro studies have shown that FTY720 directly protects 
oligodendrocyte progenitor cells (OPC) from apoptosis (Coelho et al., 2007).  Studies 
have also shown that FTY720 acts on endothelial cells and helps to preserve vascular 
integrity and barrier function (Brinkmann et al., 2004).  It is therefore possible that these 
actions of FTY720 on vascular integrity and OPC cytoprotection could also play a role in 
the observed effects of the drug treatment.
Another observation that was made in our present study was the effect of FTY720 
on bladder function.  Drug treatment dramatically reduced post-void residuals 
immediately after SCI and reduced the number of days required to regain spontaneous 
bladder function.  This observation suggests a direct drug effect on bladder function 
independent of spinal cord recovery.  A link between FTY720 and bladder function is 
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supported by in vitro studies on rabbit bladder smooth muscle which showed that 
FTY720 can regulate detrusor muscle tone (Watterson et al., 2007).   We also noted a 
dramatic reduction in the incidence of hemorrhagic cystitis after SCI.  This phenomenon 
is known to occur after experimental SCI but the mechanism of this process has yet to be 
well characterized.  Experimental studies have linked inflammatory changes in the spinal 
cord with disruption of bladder epithelium and hemorrhage (Doggweiler et al., 1998; 
Apodaca et al., 2003).  Interestingly, studies have shown that FTY720 can act on 
endothelial cells and help to preserve vascular integrity and barrier function (Brinkmann 
et al., 2004).  Thus, it is possible that this preservation of vascular integrity is responsible 
for the reduced incidence of hemorrhagic cystitis observed in this study.
The effect of FTY720 on bladder function, although dramatic, represented a 
possible confounder and limitation of this study.  Overall, fewer UTIs were diagnosed in 
the treated as compared to vehicle group which was reflected in the number of antibiotic 
courses administered (6 vs. 14).  This difference is hypothesized to be due to the robust 
effect of treatment on bladder function.  Animals that were able to void more efficiently 
would retain less urine and therefore be at lower risk for UTI.  Theoretically, this could 
then confound our analysis since improved overall systemic status could result in 
improved clinical scores in the open-field and inclined plane.  However, there is a notable 
disparity in the time frame in which the effects of FTY720 on locomotor scores and 
bladder function are noted.  If the above conjecture were true, then no disparity should be 
present and locomotor improvement should be noted coincident with bladder function 
improvement.  Furthermore, there were no differences noted among treatment groups in 
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terms of body weight change, suggesting that overall systemic status was similar among 
the groups.  Finally, morphometric analysis also supports the neuroprotective capabilities 
of FTY720 as improved bladder function would presumably not result in enhanced tissue 
preservation in the spinal cord.  Taken together this leads us to conclude that 
administration of FTY720 enhances locomotor function independent of bladder function 
and systemic status.
Our results suggest that treatment with FTY720 not only reduces the adaptive 
immune response but also affords neuroprotection and enhances bladder function after 
injury.  Given the complexity of the posttraumatic inflammatory cascade, the results of 
this study do not clarify the role of T cells in CNS recovery.  However, these results do 
reinforce the growing body of knowledge suggesting immunomoduation as a possible 
therapeutic strategy in SCI.
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Figure A.1.  (A) Weekly hind limb evaluations were completed by putting the animals 
one at a time on an open field for 4 min.  (B) In addition, assessment of functional 
recovery included an inclined plane task.
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Figure A.2.  FTY720 treatment reduces T cell infiltration into the spinal cord after 
injury.  After SCI, animals were injected with either vehicle or FTY720 for 1, 4, or 7 d. 
A 1-cm segment of the cord centered on the impact site was then harvested from each 
animal and prepared for flow cytometry.  (A) Representative dot blots of the injury site of 
a vehicle injected animal showing the 7-AAD+ population used for analysis (Gate P5). 
(B) Representative dot blots of the injury site of a vehicle injected animal showing the 
percentages of CD3+/CD4+ double-positive cells (Gate Q2) and of (C) CD3+/CD8+ 
double-positive cells (Gate Q2) within the 7-AAD+ gate.  (D) A graphical summary of 
the mean percentages of 7-AAD+ events that were CD3+/CD4+ and CD3+/CD8+ for 
treated and vehicle animals at the various days post-injury (DPI).  As shown by this flow 
cytometric paradigm, FTY720 treatment reduces infiltration of both CD3+/CD4+ helper 
and CD3+/CD8+ cytotoxic T-cell populations into the cord after SCI.  *p < 0.05 
compared with vehicle treated rats.
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Figure A.3.  FTY720 promotes hind limb recovery after spinal cord injury.  After SCI, 
animals were randomly placed into one of three groups: injury only, vehicle, and 
FTY720-treated.  Functional assessments were performed weekly for 6 weeks.  (A) Open 
field assessment of hind limb locomotor function using the BBB scale.  Starting at week 
3, treated rats as a group performed significantly better than the control groups.  No 
significant differences were noted between vehicle and injury only groups at any time 
point.  (B) The inclined plane test.  Treated animals outperformed members of the control 
groups starting at week 2 and continued to do so for the duration of the study.  (C) For all 
time points, linear regression analysis revealed a very strong correlation between the 
BBB and inclined plane scores (r = 0.87).  *p < 0.05 compared with injury only and 
vehicle treated rats.
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Figure A.4.  FTY720 improves bladder function after spinal cord injury.  Manual bladder 
expression was performed three times daily for the first week after SCI and two times 
daily thereafter until spontaneous micturation was reestablished.  The residual urine 
volumes of each animal were measured and recorded during each expression session to 
provide an average daily urine volume for the first 2 weeks post-SCI. Furthermore, 
during urine collection, gross hematuria was noted when observed.  (A) The mean 
residual urine volumes of treated rats were consistently and significantly lower than that 
of the control groups.  (B) Days required until spontaneous micturation was reestablished 
as defined by an average daily volume of less than 2 ml for 3 consecutive days.  Treated 
animals did not require extended assistance in expelling urine and regained spontaneous 
bladder function by day 6.  Control animals did not reach such a milestone until day 10. 
(C) FTY720 treatment significantly reduced the incidence of gross hematuria as 
compared to control groups. *p < 0.05 compared with injury only and vehicle treated rats.
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Figure A.5.  FTY720 treatment does not adversely affect body weight.  Animal body 
weights were measured and recorded throughout the duration of the behavioral outcome 
study. Treatment with FTY720 did not affect body weight following SCI. (The horizontal 
axis is presented on a logarithmic scale.)
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Figure A.6.  Myelin sparing correlates with locomotor recovery.  At the conclusion of 
the behavioral outcome study (6 weeks post-SCI), animals were sacrificed and cords 
were harvested and cryosectioned.  Sections at the level of the SCI epicenter were stained 
with EC to determine the extent of white matter sparing.  (A) A representative EC-stained 
cross-section at the level of the SCI epicenter from a vehicle animal.  (B) A comparable 
section from a FTY720-treated animal.  (C) At the level of the SCI epicenter, FTY720 
treatment resulted in a significant increase in the percentage of spared myelin as 
compared to vehicle treatment.  (D) A linear regression analysis of the final BBB 
locomotor scores and spared myelin percentages at the epicenter exhibited a very strong 
correlation (r = 0.75).  (E) In addition to the myelin sparing analysis completed at the 
injury epicenter, adjacent cord sections of every 0.5 mm up to 5 mm away from the 
epicenter were similarly processed and analyzed.  This analysis revealed that FTY720 
treatment resulted in a significant increase in the percentage of spared myelin as 
compared to vehicle treatment in adjacent areas of the injury epicenter, especially regions 
caudal.  (Negative distances on horizontal axis denote rostral direction whereas positive 
denote caudal direction.)  Scale bars (A and B) = 300 μm.  *p < 0.05 compared with 
vehicle treated rats.
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BBB Locomotor Rating Scale
0 No observable hind limb movement
1 Slight movement of one or two joints, usually the hip and/or knee
2 Extensive movement of one joint or extensive movement of one joint and slight movement of one other joint
3 Extensive movement of two joints
4 Slight movement of all three joints of the hind limb
5 Slight movement of two joints and extensive movement of the third
6 Extensive movement of two joints and slight movement of the third
7 Extensive movement of all three joints of the hind limb
8 Sweeping with no weight support or plantar placement of the paw with no weight support
9 Plantar placement of the paw with weight support in stance only (i.e., when stationary) or occasional, 
frequent, or consistent weight supported dorsal stepping and no plantar stepping
10 Occasional weight supported plantar steps, no forelimb-hind limb coordination
11 Frequent to consistent weight supported plantar steps and no forelimb-hind limb coordination
12 Frequent to consistent weight supported plantar steps and occasional forelimb-hind limb coordination
13 Frequent to consistent weight supported plantar steps and frequent forelimb-hind limb coordination
14 Consistent weight supported plantar steps, consistent forelimb-hind limb coordination; and predominant paw 
position during locomotion is rotated (internally or externally) when it makes initial contact with the surface 
as well as just before it is lifted off at the end of stance or frequent plantar stepping, consistent forelimb-hind 
limb coordination, and occasional dorsal stepping
15 Consistent plantar stepping and consistent forelimb-hind limb coordination; and no toe clearance or occasional 
toe clearance during forward limb advancement; predominant paw position is parallel to the body at initial 
contact
16 Consistent plantar stepping and consistent forelimb-hind limb coordination during gait; and toe clearance 
occurs frequently during forward limb advancement; predominant paw position is parallel at initial contact 
and rotated at lift off
17 Consistent plantar stepping and consistent forelimb-hind limb coordination during gait; and toe clearance 
occurs frequently during forward limb advancement; predominant paw position is parallel at initial contact 
and lift off
18 Consistent plantar stepping and consistent forelimb-hind limb coordination during gait; and toe clearance 
occurs consistently during forward limb advancement; predominant paw position is parallel at initial contact 
and rotated at lift off
19 Consistent plantar stepping and consistent forelimb-hind limb coordination during gait; and toe clearance 
occurs consistently during forward limb advancement; predominant paw position is parallel at initial contact 
and lift off; and tail is down part or all of the time
20 Consistent plantar stepping and consistent coordinated gait; consistent toe clearance; predominant paw 
position is parallel at initial contact and lift off; tail consistently up; and trunk instability
21 Consistent plantar stepping and coordinated gait, consistent toe clearance, predominant paw position is 
parallel throughout stance, consistent trunk stability, tail consistently up
Terms and Operational Definitions
Slight partial joint movement through less than half the range of joint motion
Extensive movement through more than half of the range of joint motion
Sweeping rhythmic movement of hind limb in which all three joints are extended, then fully flex and extend again; 
animal is usually lying on its side, the plantar surface of paw may or may not contact the ground; no weight 
support across the hind limb is evident
No Weight Support no contraction of the extensor muscles of the hind limb during plantar placement of the paw; or no elevation 
of the hindquarter
Weight Support contraction of the extensor muscles of the hind limb during plantar placement of the paw, or elevation of the 
hindquarter
Plantar Stepping paw is in plantar contact with weight support then the hind limb is advanced forward and plantar contact with 
weight support is reestablished
Dorsal Stepping weight is supported through the dorsal surface of the paw at some point in the step cycle
forelimb-hind limb 
Coordination
for every forelimb step an hind limb step is taken and the hind limbs alternate
Occasional less than or equal to half; <50%
Frequent more than half but not always; 51-94%
Consistent nearly always or always; 95-100%
Trunk Instability lateral weight shifts that cause waddling from side to side or a partial collapse of the trunk
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Table A.1.  The 21-point BBB locomotor scale used to rate functional recovery after 
SCI.  (Adapted from Basso et al., 1995)
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Percentage of Animals within Each Group Reaching Locomotor Milestones
Day 28 Post-Injury Day 35 Post-Injury Day 42 Post-Injury
PS C PS C PS C
Injury Only 44.4% (4/9) 11.1% (1/9) 55.6% (5/9) 11.1% (1/9) 66.7% (6/9) 33.3% (3/9)
Vehicle 50% (5/10) 10% (1/10) 70% (7/10) 20% (2/10) 80% (8/10) 20% (2/10)
FTY 720 81.8% (9/11)* 63.6% (7/11)** 100% (11/11)* 63.6% (7/11)** 100% (11/11)* 81.8% (9/11)**
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Table A.2.  Animals treated with FTY720 are more likely to reach locomotor milestones. 
Frequency analysis of rats achieving consistent plantar stepping (PS) or occasional 
coordination (C) between 4 and 6 weeks after injury.  *p < 0.05 compared with injury 
only and vehicle treated rats.  **p < 0.005 compared with injury only and vehicle treated
rats.
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